Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

ABSTRACT

The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of Provisional Patent ApplicationSerial No. 60/049,871, filed Jun. 16, 1997, which application isspecifically incorporated herein by reference. The followingapplications, listed by serial number and filing date, contain materialpertaining to this application: Ser. No. 08/458,418 filed on Jun. 2,1995, Ser. No. 08/472,716 filed on Jun. 6, 1995, and Ser. No. 08/471,285filed on Jun. 6, 1995.

FIELD OF THE INVENTION

This invention in the fields of immunology and infectious diseasesrelates to antibodies that are specific for Gram positive bacteria,particularly to lipoteichoic acids exposed on the surface of thebacteria. The invention includes monoclonal and chimeric antibodies, aswell as fragments, regions and derivatives thereof. This invention alsorelates to the epitope to which the antibodies of the invention bind aswell as the sequences, fragments, and regions of the epitopes. Both theantibodies and peptides that encompass the epitope, and regions andfragments thereof, may be used for diagnostic, prophylactic andtherapeutic applications.

BACKGROUND OF THE INVENTION

Man has long battled bacterial infections, and no one can doubt thetremendous successes obtained. Before the discovery and development ofantibiotics, death due to a bacterial infection was frequently rapid andinevitable. Surgical procedures and sanitary conditions have vastlyimproved from the time when amputation was associated with a 50 percentmortality rate.

Nonetheless, the battle has not been won. Undoubtedly a significant partof the problem is that bacteria are the product of nearly 3 billionyears of natural selection from which they have emerged as an immenselydiverse group of organisms that colonize almost all parts of the worldand its inhabitants. To begin to understand bacteria requirescategorization, and the most fundamental categories for bacteria aretheir response to the Gram stain, yielding (for the most part) Grampositive bacteria and Gram negative bacteria.

The difference in response to the Gram stain results from differences inbacterial cell walls. The cells walls of Gram negative bacteria are madeup of a unique outer membrane of two opposing phospholipid-proteinleaflets, with an ordinary phospholipid in the inner leaflet but theextremely toxic lipopolysaccharide in the outer leaflet. The cell wallsof Gram positive bacteria seem much simpler in comparison, containingtwo major components, peptidoglycan and teichoic acids plus additionalcarbohydrates and proteins depending on the species.

Of the Gram positive bacteria, one of the most common genera isStaphylococcus. Staphylococci commonly colonize humans and animals andare an important cause of human morbidity and mortality, particularly inhospitalized patients. Staphylococci are prevalent on the skin andmucosal linings and, accordingly, are ideally situated to produce bothlocalized and systemic infections.

There are two main groups of Staphylococci divided according to theproduction of “coagulase,” an enzyme that causes fibrin to coagulate andto form a clot: coagulase positive and coagulase negative. The coagulasepositive Staphylococcus species most frequently pathogenic in humans isStaphylococcus aureus. S. aureus is the most virulent Staphylococcus andproduces severe and often fatal disease in both normal andimmunocompromised hosts. Staphylococcus epidermidis is the most commoncoagulase negative species.

In recent years, S. epidermidis has become a major cause of nosocomialinfection in patients whose treatments include the placement of foreignobjects such as cerebrospinal fluid shunts, cardiac valves, vascularcatheters, joint prostheses, and other implants into the body. S.epidermidis and S. aureus are common causes of post-operative woundinfections and S. epidermidis has also become a common cause ofperitonitis in patients with continuous ambulatory peritoneal dialysis.In a similar manner, patients with impaired immunity and those receivingparenteral nutrition through central venous catheters are at high riskfor developing S. epidermidis sepsis. (C. C. Patrick, J. Pediatr.,116:497 (1990)). S. epidermidis is now recognized as a common cause ofneonatal nosocomial sepsis. Infections frequently occur in prematureinfants that have received parenteral nutrition which can be a direct orindirect source of contamination.

Staphylococcal infections are difficult to treat for a variety ofreasons. Resistance to antibiotics is common and becoming more so. SeeL. Garrett, The Coming Plague, “The Revenge of the Germs or Just KeepInventing New Drugs”Ch. 13, pgs. 411-456, Farrar, Straus and Giroux, NY,Eds. (1994). In one study, the majority of Staphylococci isolated fromblood cultures of septic infants were multiply resistant to antibiotics(A. Fleer et al., Pediatr. Infect. Dis. 2:426 (1983)). A more recentstudy describes methicillin-resistant S. aureus (J. Romero-Vivas, etal., Clin. Infect. Dis. 21:1417-23 (1995)) and a recent review notesthat the emergence of antibiotic resistance among clinical isolatesmakes treatment difficult (J. Lee., Trends in Micro. 4(4):162-66 (April1996). Recent reports in the popular press also describe troublingincidents of antibiotic resistance. See The Washington Post “Microbe inHospital Infections Show Resistance to Antibiotics,” May 29, 1997; TheWashington Times, “Deadly bacteria outwits antibiotics,” May 29, 1997.

In addition, host resistance to Staphylococcal infections is not clearlyunderstood. Opsonic antibodies have been proposed to prevent or treatStaphylococcal infections. See U.S. Pat. No. 5,571,511 to G. W. Fischerissued Nov. 5, 1996, specifically incorporated by reference. Themicrobial targets for these antibodies have been capsularpolysaccharides or surface proteins. As to capsular polysaccharides, theimmunization studies of Fattom et al., J. Clin. Micro. 30(12):3270-3273(1992) demonstrated that opsonization was related to S. epidermidistype-specific anti-capsular antibody, suggesting that S. epidermidis andS. aureas have a similar pathogenesis and opsonic requirement as otherencapsulated Gram positive cocci such as Streptococcus pneumonia. As tosurface proteins, Timmerman, et al., J. Med. Micro. 35:65-71 (1991)identified a surface protein of S. epidermidis that was opsonic for thehomologous strain used for immunization and for monoclonal antibodyproduction. While other monoclonal antibodies were identified that boundto non-homologous S. epidermidis strains, only the monoclonal antibodyproduced to the homologous strain was opsonic and opsonization wasenhanced only to the homologous strain but not to heterologous strains.Accordingly, based on the studies of Fattom et al., and Timmerman etal., and others in the field (and in contrast to our own studies), onewould not expect that an antibody that is broadly reactive to multiplestrains of S. epidermidis and to S. aureus would have opsonic activityagainst both. This is particularly true for antibodies that bind to bothcoagulase positive and coagulase negative Staphylococci.

Accordingly, there is a need in the art to provide monoclonal antibodiesthat can bind to Staphylococcus of both coagulase types and that canenhance phagocytosis and killing of the bacteria and thereby enhanceprotection in vivo. There is also a need in the art for the epitope ofthe site to which such antibodies can bind so that other antibodies withsimilar abilities can be identified and isolated.

There is a related need in the art for humanized or other chimerichuman/mouse monoclonal antibodies. In recent well publicized studies,patients administered murine anti-TNF (tumor necrosis factor) monoclonalantibodies developed anti-murine antibody responses to the administeredantibody. (Exley A. R., et al., Lancet 335:1275-1277 (1990)). This typeof immune response to the treatment regimen, commonly referred to as theHAMA response, decreases the effectiveness of the treatment and may evenrender the treatment completely ineffective. Humanized or chimerichuman/mouse monoclonal antibodies have been shown to significantlydecrease the HAMA response and to increase the therapeuticeffectiveness. See LoBuglio et al., P.N.A.S. 86:4220-4224 (June 1989).

SUMMARY OF THE INVENTION

To address these needs in the art, the present invention encompassesopsonic and protective monoclonal and chimeric antibodies that bind tolipoteichoic acid of Gram positive bacteria. The antibodies also bind towhole bacteria and enhance phagocytosis and killing of the bacteria invitro and enhance protection from lethal infection in vivo. The mousemonoclonal antibody has been humanized and the resulting chimericantibody provides a previously unknown means to diagnose, prevent and/ortreat infections caused by gram positive bacteria bearing lipoteichoicacids. This invention also encompasses a peptide mimic of thelipoteichoic acid epitope binding site defined by the monoclonalantibody. This epitope or epitope peptide mimic identifies otherantibodies that may bind to the lipoteichoic acid epitope. Moreover, theepitope or epitope peptide mimic provides a valuable substrate for thegeneration of vaccines or other therapeutics.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides a schematic representation of lipoteichoic acid (LTA) inthe Gram positive bacterial cell wall.

FIG. 2 depicts antibody regions, such as the heavy chain constant region(C_(H)), the heavy chain variable region (V_(H)), the light chainconstant region (C_(L)), and the light chain variable region (V_(L)).

FIG. 3 demonstrates the enhancement of survival after administration ofMAB 96-110 in a lethal neonatal model of coagulase positivestaphylococcus sepsis.

FIG. 4 demonstrates enhancement of survival in adult mice infected withcoagulase negative staphylococci after administration of MAB 96-110.Approximately 23 hours after infection, 70% of the animals treated withMAB 96-110 were alive compared with 20% of animals not given antibody.

FIG. 5 (SEQ ID NOS 4 & 5, and 6 & 7, respectively) provides a list of 18resulting sequences for the 6 mer library panning.

FIG. 6 (SEQ ID NOS 8-43, respectively) provides a list of the 18resulting sequences for the second experiment 15 mer library panning.

FIG. 7 (SEQ ID NOS 44 & 45, and 46 & 47, and 48 & 49, respectively)provides a list of the 17 resulting sequences for the first experiment15 mer library panning.

FIG. 8 (SEQ ID NOS 50-67, respectively) provides a master list compiledfrom the common resulting peptide sequences from all the pannings.

FIG. 9 sets forth a comparison of the optical density signals of eachphage isolate at 6.25×10¹¹ vir/ml.

FIG. 10 shows the strategy for cloning the variable region genefragments.

FIG. 11 (SEQ ID NOS 68-85, respectively) lists the oligonucleotidesprimers used.

FIG. 12 (SEQ ID NOS 86-89, respectively) provides the final consensusDNA sequence of the heavy and light chain variable regions.

FIG. 13 demonstrates the re-amplification of the variable region genefragments.

FIG. 14 sets forth the plasmid map for pJRS334.

FIG. 15 provides the results of the antibody production assay, showingthat the transfection of cells with the plasmid construct results in theproduction of a molecule containing both human IgG and kappa domains.

FIG. 16 provides the results of the activity assay, demonstrating thatthe transfection of cells with the plasmid construct results in theproduction of a molecule that binds to the Hay antigen.

FIG. 17 depicts the opsonic activity of the chimeric monoclonal antibody96-110 for S. epidermidis in a neutrophil mediated opsonophagocyticbactericidal assay.

FIG. 18 demonstrates the enhancement of survival after administration ofMAB 96-110 in a lethal model of S. epidermidis sepsis.

FIG. 19 depicts the effect of the chimeric monoclonal antibody 96-110 onthe survival of adult mice after intraperitoneal challenge with S.epidermidis.

FIG. 20 sets forth the effect of the chimeric monoclonal antibody 96-110on bacteremia in a lethal S. epidermidis model.

FIG. 21 depicts bacteremia levels four hours after infection with S.epidermidis at different doses of the chimeric monoclonal antibody96-110.

FIG. 22 sets forth the effect of the chimeric monoclonal antibody 96-110on survival in a lethal neonatal S. epidermidis sepsis model.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides anti-lipoteichoic acid (LTA) murineantibodies (including monoclonal antibodies) and chimeric murine-humanantibodies, and fragments, derivatives, and regions thereof, which bindto and opsonize whole Gram positive cocci such as Staphylococcus tothereby enhance phagocytosis and killing of such bacteria in vitro andwhich enhance protection from lethal infection of such bacteria in vivo.The antibodies, fragments, regions, and derivatives thereof of theinvention preferably recognize and bind to an epitope of LTA that canblock the binding of Gram positive bacteria to epithelial cells, such ashuman epithelial cells. Accordingly, the invention provides broadlyreactive and opsonic antibodies for the diagnosis, prevention, and/ortreatment of bacterial infections caused by Gram positive bacteria.

The antibodies of the invention are broadly reactive with Gram positivebacteria, meaning that they selectively recognize and bind to Grampositive bacteria and do not recognize or bind to Gram negativebacteria. Any conventional binding assay can be used to assess thisbinding, including for example, the enzyme linked immunosorbent assaydescribed below. The basis of the binding is the presence of LTA exposedon the surface of the cell wall of Gram positive bacteria.

As noted above, the cell walls of Gram positive bacteriacharacteristically contain peptidoglycans such as murein as well asteichoic acids. Teichoic acids are polymers of either glycerol phosphateor ribitol phosphate with various sugars, amino sugars, and amino acidsas substituents. Although the lengths of the chains and the nature andlocation of the substituents vary from species to species and sometimesbetween species, in general teichoic acids make up a major part of thecell wall. The teichoic acids related to this invention are lipoteichoicacids which are teichoic acids made up of glycerol phosphate which isprimarily linked to a glycolipid in the underlying cell membrane.Although the precise structure of LTA in the Gram positive bacterialcell wall is not known, a standard schematic representation commonlyaccepted in the art is set forth in FIG. 1. Accordingly, the antibodiesof the claimed invention are broadly reactive because they recognize andbind to the lipoteichoic acids that are characteristically surfaceexposed on Gram positive bacteria.

The antibodies of the invention are also opsonic, or exhibit opsonicactivity, for Gram positive bacteria. As those in the art recognize,“opsonic activity” refers to the ability of an opsonin (generally eitheran antibody or the serum factor C3b) to bind to an antigen to promoteattachment of the antigen to the phagocyte and thereby enhancephagocytosis. Certain bacteria, especially encapsulated bacteria whichresist phagocytosis due to the presence of the capsule, become extremelyattractive to phagocytes such as neutrophils and macrophages when coatedwith an opsonic antibody and their rate of clearance from thebloodstream is strikingly enhanced. Opsonic activity may be measured inany conventional manner as described below.

The ability of the anti-LTA antibodies of the invention to bind to andopsonize Gram positive bacteria and thereby enhance phagocytosis andcell killing in vitro and to enhance protection in vivo is completelyunexpected because anti-LTA antibodies have been reported to lackopsonic activity. Indeed, anti-LTA antibodies have been often used ascontrols.

For example, Fattom et al., J. Clin. Micro. 30(12):3270-3273 (1992)examined the opsonic activity of antibodies induced against typespecific capsular polysaccharide of S. epidermidis, using as controlsantibodies induced against techoic acids and against S. hominus. Whiletype-specific antibodies were highly opsonic, anti-techoic acidantibodies were not different from the anti-S. hominus antibodies.

Similarly, in Kojima et al., J. Infect. Dis. 162:435-441 (1990), theauthors assessed the protective effects of antibody to capsularpolysaccharide/adhesion against catheter-related bacteremia due tocoagulase negative Staphylococci and specifically used a strain of S.epidermidis that expresses teichoic acid as a control. See page 436,Materials and Methods, left column, first ¶; right column, third ¶. In alater study, the authors reached a more explicit conclusion against theutility of anti-techoic antibodies:

Immunization protocols designed to elicit antibody to techoic acid butnot to PS/A afforded no protection against bacteremia or endocarditis.

Takeda, et al., Circulation 86(6):2539-2546 (1991).

Contrary to the prevailing view in the field, the broadly reactiveopsonic antibodies against the LTA of Gram positive bacteria, includingS. aureus and S. epidermidis, of the invention satisfy a clear need inthe art. As described in the background section, both S. aureus and S.epidermidis are common causes of post-operative wound infections; S.epidermidis has become a major cause of nosocomial infections inpatients whose treatments include the placement of foreign objects; S.epidermidis has become a common cause of peritonitis in patients withcontinuous ambulatory peritoneal dialysis; and S. epidermidis is nowrecognized as a common cause of neonatal sepsis.

Indeed, our laboratory has recently focused tremendous efforts to findbroadly opsonic antibodies as detailed in a recent series of fourrelated applications and one issued patent, specifically:

U.S. Ser. No. 08/296,133, filed Aug. 26, 1994, of Gerald W. Fischer,entitled “Directed Human Immune Globulin for the Prevention ofStaphylococcal Infections;”

U.S. Pat. No. 5,571,511, issued Nov. 5, 1996 to Gerald W. Fischer,entitled “Broadly Reactive Opsonic Antibodies that React with CommonStaphylococcal Antigens;”

U.S. Ser. No. 08/466,059, filed Jun. 6, 1995, of Gerald W. Fischer,entitled “In Vitro Methods for Identifying Pathogenic Staphylococcus,For Identifying Immunoglobulin Useful for the Treatment of PathogenicStaphylococcus Infections, and In Vitro Methods Employing suchimmunoglobulins;” and

U.S. Ser. No 08/308,495, filed Sep. 21, 1994, of to Gerald W. Fischer,entitled “Broadly Reactive Opsonic Antibodies that React with CommonStaphylococcal Antigens,”

all of which are specifically incorporated herein by reference.

This series of applications and the issued patent describe the searchfor broadly reactive opsonic antibodies particularly againstStaphylococci. In rough chronological order, the “Directed Human ImmuneGlobulin” application describes the selection and use of Directed HumanImmune Globulin to prevent or treat infections caused by S. epidermidiswhich contains antibodies with the ability to bind to surface antigensof S. epidermidis in an ELISA and the exhibition of greater than 80%opsonophagocytic bactericidal activity against S. epidermidis in aparticularly described in vitro assay. The issued patent claimsdescribes for the first time a particular strain of S. epidermidis thatidentifies broadly reactive opsonic antibodies against both coagulasepositive and coagulase negative Staphylococci and specifically claims anantigen preparation isolated from S. epidermidis strain Hay ATCC 55133,deposited on Dec. 19, 1990, which generates broadly reactive opsonicantibody which specifically reacts in an assay with S. epidermidisserotypes I, II and III, and which exhibits opsonic activity greaterthan 70%. The “In Vitro Methods” application describes the use of aSerotype II S. epidermidis, such as the Hay strain, that identifiespathogenic Staphylococcus infections. The fourth application in thechain describes a surface protein identified on the Hay strain that caninduce broadly reactive opsonic antibodies.

Nonetheless, the search continued for antibodies, both polyclonal andmonoclonal, that are broadly reactive and opsonic against all Grampositive bacteria and has culminated in the present invention. Havingdiscovered the Hay strain and determined its unique ability to generatebroadly opsonic antibodies against Staphylococci, it was used as thebasis for this search.

As set forth in Example 1, mice were immunized with whole strain Hay S.epidermidis from which hybridomas were produced. In screening thehybridomas for antibodies, the antibodies of one clone (first designated96-105CE11 IF6 and later designated 96-110 MAB) exhibited a strong IgGreaction (Tables 1 and 2) and, in further tests, was found to bind verystrongly to Gram positive bacteria such as to strain Hay, to all threeserotypes of S. epidermidis, to S. hemolyticus, S. hominus, and twoserotypes of S. aureus (Tables 3-6) but not to the Gram negativecontrol, Haemophilus influenza.

Similar to the antibodies described in the Fischer applications andpatent set forth above, the antibody of the present invention exhibitsvery strong binding, i.e., O.D.s of around twice background in anenzyme-linked immunosorbent assay (described below), against strain Hay.In a preferred embodiment, the level of high binding is equal to orgreater than five times background. In other embodiments, the level ofhigh binding is equal to or greater than 10 times background. Of course,any meaningful increase over background (the level observed when all thereagents other than the antibody being tested) will be recognized byskilled persons in the art as high binding and therefor within the scopeof the invention.

Also as described in the Fischer applications and patent, high bindinghas been found to correlate with opsonic activity. As set forth inExample 2, in a neutrophil mediated bactericidal assay (describedbelow), the 96-110 MAB exhibited enhanced opsonization against theprototypic coagulase negative bacteria, S. epidermidis, and against theprototypic coagulase positive bacteria, S. aureus. With this level ofopsonic activity, an antibody should enhance phagocytosis and cellkilling of both coagulase negative and coagulase positive bacteria.

The term “enhanced” refers to activity that measurably exceedsbackground at a valuable level. The level deemed valuable may well varydepending on the specific circumstances of the infection, including thetype of bacteria and the severity of the infection. For example, forenhanced opsonic or phagocytic activity, in a preferred embodiment, anenhanced response is equal to or greater than 75% over background. Inanother preferred embodiment, the enhanced response is equal to orgreater than 80% over background. In yet another embodiment, theenhanced response is equal to or greater than 90% over background.

To confirm that the antibody, previously shown to be broadly reactive aswell as opsonic, would be protective in vivo, MAB 96-110 was assessed ina lethal infection model in both neonatal rats and adult mice. As setforth in Example 3, survival in control animals given either no therapy,saline, or control MAB, ranged from 0 to less than 10%. However, MAB96-110 enhanced the survival to 50% or greater.

Where, as here, the enhancement measured is of survival, the preferredincrease over background may be more modest than above. Thus, anincrease in survival of 25% may be an enhanced response. In otherembodiments, enhanced survival may be greater than 50%. Again, theperson of skill in the art would recognize other meaningful increases insurvival as within the invention.

In view of the impressive opsonic activity in vitro as well as theprotective activity in vivo of MAB 96-110, we sought the identity of theepitope of the antigen to which it bound. An “antigen” is a molecule ora portion of a molecule capable of being bound by an antibody and whichis also capable of inducing an animal to produce antibody capable ofbinding to an epitope of that antigen. An antigen may have one or moreepitopes. An “epitope” analogously means that portion of the moleculethat is capable of being recognized by and bound by an antibody. Ingeneral, epitopes consist of chemically active surface groupings ofmolecules such as amino acids or sugar side chains that have specifiedthree dimensional structural and specific charge characteristics.

In a series of panning experiments set forth in Examples 4-6, weidentified peptide sequences to which MAB 96-110 bound strongly. Thesesequences provide at least peptide mimics of the epitope to which MAB96-110 bound. Thus, one aspect of the present invention involves apeptide having the sequence

WRMYFSHRHAHLRSP(SEQ ID NO 1)

and another aspect of the invention involves a peptide having thesequence

WHWRHRIPLQLAAGR(SEQ ID NO 2).

Of course, the epitope of the invention may be identical to one of thesesequences or may be substantially homologous to these sequences suchthat the anti-LTA antibodies of the invention will bind to them.Alternatively, the substantially homologous sequences of the inventionare those that are able to induce the anti-LTA antibodies of theinvention. Other peptide epitope mimics within the invention may vary inlength and sequence from these two peptides.

The present invention also encompasses recombinant epitopes, epitopemimics, and antigens. The DNA sequence of the gene coding for theisolated antigen can be identified, isolated, cloned, and transferred toa prokaryotic or eukaryotic cell for expression by procedures well-knownin the art. For example, procedures are generally described in Sambrooket al., Molecular Cloning, A Laboratory Manual, 2nd Ed., Cold SpringsHarbor Press, Cold Spring Harbor, N.Y. (1989) incorporated by reference.

To confirm the specificity of the peptides for the monoclonal antibody,it was tested in a competitive inhibition assay and found to inhibitbinding of MAB 96-110 to strain Hay. See Example 6.

To determine the protein of which such sequences are a part, we comparedthe peptide sequences to the sequences of proteins but, as set forth inExample 7, failed to identify any known protein. Accordingly, weexpanded our search of other antigen candidates. Because the peptidesequence was small and had successfully inhibited the binding of MAB96-110 to strain Hay and because MAB 96-110 bound to and opsonized allthree serotypes of S. epidermidis as well as to both coagulase negativeand coagulase positive bacteria, we assessed the possibility that thepeptide was part of a surface exposed lipoteichoic acid. To oursurprise, as set forth in Example 7, we found that MAB 96-110 bound tothe LTAs of several Gram positive bacteria such as S. mutans, S. aureus,S. faecalis, S. pyogenes (group A Streptococcus).

Thus, the present invention includes antibodies that are capable ofbinding to the LTA of Gram positive bacteria, including both coagulasenegative and coagulase positive bacteria, and of enhancing theopsonization of such bacteria. These anti-LTA antibodies includepolyclonal antibodies as well as monoclonal antibodies produced by thehybridomas of the invention, such as MAB 96-110 as well as othermonoclonal antibodies, fragments and regions thereof, as well asderivatives thereof. As set forth above, the strength of the binding mayrange from twice above background, to five- and ten-times abovebackground. In addition, the antibodies, fragments, regions, andderivatives of the present invention are capable of enhancing theopsonization of such bacteria, at rates ranging from 75% and up.

The “fragments” of the antibodies of the invention include, for example,Fab, Fab′, F(ab′)₂, and SF_(V). These fragments are produced from intactantibodies using methods well known in the art such as, for example,proteolytic cleavage with enzymes such as papain (to produce Fabfragments) or pepsin (to produce F(ab′)₂). The “regions” of theantibodies of the present invention include a heavy chain constantregion (H_(C) or C_(H)), a heavy chain variable region (H_(V) or V_(H)),a light chain constant region (L_(C) or C_(L)), and a light chainvariable region (L_(V) or V_(L)) (FIG. 2). The light chains may beeither a lambda or a kappa chain.

In a preferred aspect of the invention, the regions include at least oneheavy chain variable region or a light chain variable region which bindsa portion of LTA, including for example the specific antigen bindingsites (that which binds to the epitope) of the two regions. In anotherembodiment, these two variable regions can be linked together as asingle chain antibody. While a full length heavy chain may be criticalfor opsonic activity and enhance anti-cytokine (anti-inflammatory)activity, the antibody fragments encompassing the variable regions maybe suitable for inhibition of bacterial binding to epithelial cells andmay also be anti-inflammatory.

In a particularly preferred aspect of the invention, the antibody is achimeric mouse/human antibody made up of regions from the anti-LTAantibodies of the invention together with regions of human antibodies.For example, a chimeric H chain can comprise the antigen binding regionof the heavy chain variable region of the anti-LTA antibody of theinvention linked to at least a portion of a human heavy chain constantregion. This humanized or chimeric heavy chain may be combined with achimeric L chain that comprises the antigen binding region of the lightchain variable region of the anti-LTA antibody linked to at least aportion of the human light chain constant region.

The chimeric antibodies of the invention may be monovalent, divalent, orpolyvalent immunoglobulins. For example, a monovalent chimeric antibodyis a dimer (HL) formed by a chimeric H chain associated throughdisulfide bridges with a chimeric L chain, as noted above. A divalentchimeric antibody is a tetramer (H₂ L₂) formed by two HL dimersassociated through at least one disulfide bridge. A polyvalent chimericantibody is based on an aggregation of chains.

A particularly preferred chimeric antibody of the invention is describedin Examples 8-10 which set forth in detail the preparation of apreferred chimeric IgG antibody (and in Examples 11-13 which describethe functional activity of this preferred chimeric anibody). Of course,other chimeric antibodies composed of different sections of the anti-LTAantibodies of the invention are within the invention. In particular, theheavy chain constant region can be an IgM or IgA antibody.

In addition to the protein fragments and regions of the antibodies, thepresent invention also encompasses the DNA sequence of the gene codingfor the antibodies as well as the peptides encoded by the DNA.Particularly preferred DNA and peptide sequences are set forth in FIG.12. That figure provides the variable regions of both the heavy andlight chains of MAB 96-110, including the Complementarity DeterminingRegions (“CDR”), the hypervariable amino acid sequences within antibodyvariable regions which interact with amino acids on the complementaryantigen. The invention includes these DNA and peptide sequences as wellas DNA and peptide sequences that are homologous to these sequences. Ina preferred embodiment, these sequences are 70 % homologous althoughother preferred embodiments include sequences that are 75%, 80%, 85%,90%, and 95% homologous. Determining these levels of homology for boththe DNA and peptide sequence is well within the routine skill of thosein the art.

The DNA sequences of the invention can be identified, isolated, cloned,and transferred to a prokaryotic or eukaryotic cell for expression byprocedures well-known in the art. Such procedures are generallydescribed in Sambrook et al., supra, as well as Current Protocols inMolecular Biology (Ausubel et al., eds., John Wiley & Sons, 1989),incorporated by reference. In one preferred embodiment, the CDR can begraphed onto any human antibody frame using techniques standard in theart, in such a manner that the CDR maintains the same bindingspecificity as in the intact antibody.

In addition, the DNA and peptide sequences of the antibodies of theinvention, including both monoclonal and chimeric antibodies, may formthe basis of antibody “derivatives,” which include, for example, theproteins or peptides encoded by truncated or modified genes. Suchproteins or peptides may function similarly to the antibodies of theinvention. Other modifications, such as the addition of other sequencesthat may enhance the effector function, which includes phagocytosisand/or killing of the bacteria, are also within the present invention.

The present invention also discloses a pharmaceutical compositioncomprising the anti-LTA antibodies, whether polyclonal, monoclonal orchimeric, as well as fragments, regions, and derivatives thereof,together with a pharmaceutically acceptable carrier. The pharmaceuticalcompositions of the invention may alternatively comprise the isolatedantigen, epitope, or portions thereof, together with a pharmaceuticallyacceptable carrier.

Pharmaceutically acceptable carriers can be sterile liquids, such aswater, oils, including petroleum oil, animal oil, vegetable oil, peanutoil, soybean oil, mineral oil, sesame oil, and the like. Withintravenous administration, water is a preferred carrier. Salinesolutions, aqueous dextrose, and glycerol solutions can also be employedas liquid carriers, particularly for injectable solutions. Suitablepharmaceutical carriers are described in Remington's PharmaceuticalSciences, 18th Edition (A. Gennaro, ed., Mack Pub., Easton, Pa., 1990),incorporated by reference.

Finally, the present invention provides methods for treating a patientinfected with, or suspected of being infected with, a Gram positivebacteria such as a staphylococcal organism. The method comprisesadministering a therapeutically effective amount of a pharmaceuticalcomposition comprising the anti-LTA immunoglobulin (whether polyclonalor monoclonal or chimeric, including fragments, regions, and derivativesthereof) and a pharmaceutically acceptable carrier. A patient can be ahuman or other mammal, such as a dog, cat, cow, sheep, pig, or goat. Thepatient is preferably a human.

A therapeutically effective amount is an amount reasonably believed toprovide some measure of relief or assistance in the treatment of theinfection. Such therapy as above or as described below may be primary orsupplemental to additional treatment, such as antibiotic therapy, for astaphylococcal infection, an infection caused by a different agent, oran unrelated disease. Indeed, combination therapy with other antibodiesis expressly contemplated within the invention.

A further embodiment of the present invention is a method of preventingsuch infections, comprising administering a prophylactically effectiveamount of a pharmaceutical composition comprising the anti-LTA antibody(whether polyclonal or monoclonal or chimeric, including fragments,regions, and derivatives thereof) and a pharmaceutically acceptablecarrier.

A prophylactically effective amount is an amount reasonably believed toprovide some measure of prevention of infection by Gram positivebacteria. Such therapy as above or as described below may be primary orsupplemental to additional treatment, such as antibiotic therapy, for astaphylococcal infection, an infection caused by a different agent, oran unrelated disease. Indeed, combination therapy with other antibodiesis expressly contemplated within the invention.

In another embodiment, the peptide which mimics the LTA epitope would beuseful to prevent binding of Gram positive bacteria to epithelial cellsand thereby inhibit colonization. For example, a pharmaceuticalcomposition containing such a peptide may be administered intranasallyto prevent an infection or to minimize a current infection.

Yet another preferred embodiment of the present invention is a vaccinecomprising the epitope, epitope mimic, or other part of the LTA antigenand a pharmaceutically acceptable carrier. Upon introduction into ahost, the vaccine generates an antibody broadly protective and opsonicagainst infection by Gram positive bacteria. The vaccine may include theepitope, an epitope mimic, any mixture of epitopes and epitope mimics,the antigen, different antigens, or any combination of epitopes, epitopemimics and antigens.

Vaccinations are particularly beneficial for individuals known to be orsuspected of being at risk of infection by Gram positive bacteria. Thisincludes patients receiving body implants, such as valves, patients withindwelling catheters, patients preparing to undergo surgery involvingbreakage or damage of skin or mucosal tissue, certain health careworkers, and patients expected to develop impaired immune systems fromsome form of therapy, such as chemotherapy or radiation therapy.

Treatment comprises administering the pharmaceutical composition(including antibodies and vaccines) by intravenous, intraperitoneal,intracorporeal injection, intraarticular, intraventricular, intrathecal,intramuscular, subcutaneous, intranasally, intravaginally, orally, or byany other effective method of administration. The composition may alsobe given locally, such as by injection to the particular area infected,either intramuscularly or subcutaneously. Administration can compriseadministering the pharmaceutical composition by swabbing, immersing,soaking, or wiping directly to a patient. The treatment can also beapplied to objects to be placed within a patient, such as dwellingcatheters, cardiac values, cerebrospinal fluid shunts, joint prostheses,other implants into the body, or any other objects, instruments, orappliances at risk of becoming infected with a Gram positive bacteria,or at risk of introducing such an infection into a patient.

As a particularly valuable corollary of treatment with the compositionsof the invention (including all anti-LTA antibodies (whether polyclonalor monoclonal or chimeric, including fragments, regions, and derivativesthereof), all pharmaceutical compositions based on such antibodies, aswell as on epitope, epitope mimics, or other part of the LTA antigen andvaccines based on such epitope or antigens) is the reduction in cytokinerelease that results from the introduction of the LTA of a Gram positivebacteria. As is now recognized in the art, LTA induces cytokines,including for example tumor necrosis factor alpha, Interleukin 6, andinterferon gamma. See Takada et al., Infection and Immunity, 63(1):57-65 (January 1995). Accordingly, the compositions of the inventionmay enhance protection at three levels: (1) by binding to LTA on thebacteria and thereby blocking the initial binding to epithelial cellsand preventing subsequent invasion of the bacteria; (2) by enhancingopsonization of the bacteria and thereby enhancing clearance of thebacteria from tissues and blood; and/or (3) by binding to LTA andpartially or fully blocking cytokine release and modulating theinflammatory responses to prevent shock and tissue destruction.

Having generally described the invention, it is clear that the inventionovercomes some of the potentially serious problems described in theBackground regarding the development of antibiotic resistant Grampositive bacteria. As set forth above, Staphylococci and streptococci(such as S. faecalis) have become increasingly resistant and, with therecent spread of vancomycin resistant strains, antibiotic therapy maybecome totally ineffective.

Particular aspects of the invention are now presented in the form of thefollowing “Materials and Methods” as well as the specific Examples. Ofcourse, these are included only for purposes of illustration and are notintended to be limiting of the present invention.

MATERIALS AND METHODS Bacteria

S. epidermidis, strain Hay, was deposited at the ATCC on Dec. 19, 1990under Accession No. 55133.

Hybridoma

Hybridoma 96-110 was deposited at the ATCC on Jun. 13, 1997 underAccession No. HB-12368.

Isotype Determination Assay

Isotype was determined using an isotype kit obtained from ZymedLaboratories. The kit can be ordered under number 90-6550.

Binding Assays

In the binding assay of the invention, immunoglobulin is reacted with apreparation of a Staphylococcal organism. The binding assay ispreferably an enzyme-linked immunosorbent assay (ELISA) or aradioimmunoassay (RIA), but may also be an agglutination assay, acoagglutination assay, a calorimetric assay, a fluorescent bindingassay, or any other suitable binding assay that is known in the art. Theassay can be performed by competitive or noncompetitive procedures withresults determined directly or indirectly.

The Staphylococcus preparation may be fixed to a suitable solid support,such as a glass or plastic plate, well, bead, micro-bead, paddle,propeller, or stick. The solid support is preferably a titration plate.The fixed preparation is incubated with immunoglobulin, which isisolated or in a biological fluid such as ascites, and the amount ofbinding determined. A positive reaction occurs when the amount ofbinding observed for the test sample is greater than the amount ofbinding for a negative control. A negative control is any sample knownnot to contain antigen-specific immunoglobulin. Positive binding may bedetermined from a simple positive/negative reaction or from thecalculation of a series of reactions. This series may include samplescontaining measured amounts of immunoglobulin that specifically bind tothe fixed antigen, creating a standard curve from which the amount ofantigen-specific immunoglobulin in an unknown sample can be determined.Alternatively, antibody can be fixed to a solid support andimmunoglobulin identified by its ability to bind a bacterial preparationbound to the fixed antibodies.

The specific of the assays used in the Examples are set forth below:

Immunoassay on Methanol-Fixed Bacterial: Heat-killed bacteria weresuspended in normal saline at an OD_(0.650)=0.600. Bacteria in 5 mls ofthe suspension were pelleted by centrifugation (approximately 1800 X g,15 minutes, 10-15° C.). The supernatant was discarded and the pelletresuspended into 12 mls of methanol (MeOH). One hundred microliters ofthe suspension in MeOH was distributed into each well of Nunc MaxisorpStripwells. The MeOH was allowed to evaporate, fixing the bacteria tothe plastic. The bacteria-coated stripwells were stored in plastic bagsand used within 2 months of preparation.

For evaluation of antibodies, the bacteria-coated plates were washedonce with PBS and non-specific reactive sites on the bacteria wereblocked by the addition of 120 ul/well of a solution of 1% bovine serumalbumin (BSA) in PBS. After a 30-60 minute incubation, the wells werewashed four times with PBS containing 0.05% Tween-20 (PBS-T). Antibody,diluted in PBS-T, was then added to the wells. Supernatants were testedat a dilution of 1:2. Ascites and purified antibody were tested atdilutions indicated in the Tables. After addition of the antibody, thewells were incubated at room temperature for 30-60 minutes in adraft-free environment. The wells were again washed four times withPBS-T and each well received 95 ul of detection antibody: rabbitanti-mouse IgG, conjugated to horse radish peroxidase (HRP) and diluted1:4000 in PBS-T. The detection antibodies were specific for mouse gamma,mu or alpha heavy chains (Zymed catalog numbers 61-6020, 61-6820 or61-6720 respectively), as indicated in the Tables.

Following another 30-60 incubation at room temperature, the wells werewashed four times with PBS-T and each well received 100 ul ofone-component TMB substrate solution (Kirkegaard and Perry Labs catalognumber 50-76-05). The wells were incubated in the dark at roomtemperature for 15 minutes. The reaction was stopped by the addition of80 ul of TMB stop solution (Kirkegaard and Perry Labs catalog number50-85-05) and the absorbance of each well at 450 nm was determined usinga Molecular Devices Vmax plate reader.

Immunoassay on LTA's:

Reactivity of MAB 96-110 was measured by immunoassay on wells coatedwith LTA's. LTA's were obtained from Sigma Chemical Company and dilutedin PBS to 1 ug/ml. One hundred microliters of the 1 ug/ml solution wasdistributed into replicate Nunc Maxisorp Stripwells. The LTA wasincubated in the wells overnight at room temperature. The unboundmaterial was removed from the wells with four washes of PBS-T. The wellswere not blocked with BSA or other proteins. Antibody, diluted in PBS-T,was then added to the wells and the assay continued as described above.

Competitive Inhibition of Antibody of LTA:

In order to determine the ability of LTA to inhibit binding of MAB96-110 to wells coated with MeOH-fixed Strain Hay, a competitiveinhibition assay was performed. Wells were coated in MeOH with StrainHay and blocked with BSA as described above. Fifty ul of LTA from S.mutans, S. aureus or S. facecalis were added to duplicate wells. Sixdifferent concentrations of each LTA were tested (from 0.04 to 9.0ug/ml). LTA's were diluted in PBS-T to obtain the desiredconcentrations. Immediately after addition of the LTA, 50 ul of purifiedMAB 96-110 at 1 ug/ml was added to each well. The final dilution of theMAB 96-110 was therefore 0.5 ug/ml. Uninhibited control wells receivedonly PBS-T and MAB without LTA.

Binding of MAB 96-110 to the LTA in the PBS-T solution resulted in acomplex of MAB/LTA which was removed from the plate during thesubsequent washing step. The interaction of the MAB 96-110 with the LTAinhibited the antibody from binding to the LTA on the surface of thebacteria and thus reduced the number of MAB 96-110 molecules bound tothe MeOH-fixed strain Hay used to coat the wells. Because the number ofMAB 96-110 molecules bound to the MeOH-fixed Strain Hay was reduced, thelevel of binding of the detection antibody (rabbit anti-mouse IgG-HPR)was therefore also decreased, leading to a reduction of colordevelopment when compared to wells in which no LTA was present.

Immunoassay with Protein A Method:

In order to evaluate monoclonal antibody 96-110 for reactivity with S.aureus 5 and S. aureus 8, it was necessary to modify the immunoassayprocedure described above. Both S. aureus strains express Protein A ontheir surfaces. Because Protein A binds strongly to the constant regionof the heavy chains of gamma-globulins, it was possible that falsepositive results would be obtained due to non-specific binding of the96-110 antibody to the Protein A molecule. In order to overcome thisdifficulty, the immunoassay wells were coated with bacteria as describedabove. However, prior to the addition of the 96-110 antibody to thebacteria-coated wells, the purified monoclonal antibody (MAb) wasreacted with a solution of recombinant Protein A conjugated to HRP anddiluted 1:500 in PBS-T. This reaction was allowed to proceed for 30minutes. The wells were washed four times with PBS-T and 100 ul of thesolution of Protein A-HRP-MAb was added to the wells. The presence ofthe Protein A-HRP from the pretreatment prevented the MAb from bindingto the Protein A on the S. aureus 5 and 8. Furthermore, the binding ofthe Protein A-HRP to the constant region of the heavy chain did notinterfere with the antibody binding site on the MAb, thereby allowingevaluation of the MAb on S. aureus and other bacteria.

The Protein A-HRP-MAb was allowed to react in the coated wells for 30-60minutes at room temperature. The wells were then washed with PBS-T andTMB substrate solution was added and the assay completed as describedabove.

Opsonization Assays

An opsonization assay can be a calorimetric assay, a chemiluminescentassay, a fluorescent or radiolabel uptake assay, a cell-mediatedbactericidal assay, or any other appropriate assay known in the artwhich measures the opsonic potential of a substance and identifiesbroadly reactive immunoglobulin. In an opsonization assay, the followingare incubated together: an infectious agent, a eukaryotic cell, and theopsonizing substance to be tested, or an opsonizing substance plus apurported opsonizing enhancing substance. Preferably, the opsonizationassay is a cell-mediated bactericidal assay. In this in vitro assay, thefollowing are incubated together: an infectious agent, typically abacterium, a phagocytic cell, and an opsonizing substance, such asimmunoglobulin. Although any eukaryotic cell with phagocytic or bindingability may be used in a cell-mediated bactericidal assay, a macrophage,a monocyte, a neutrophil, or any combination of these cells, ispreferred. Complement proteins may be included to promote opsonizationby both the classical and alternate pathways.

The opsonic ability of immunoglobulin is determined from the amount ornumber of infectious agents remaining after incubation. In acell-mediated bactericidal assay, this is accomplished by comparing thenumber of surviving bacteria between two similar assays, only one ofwhich contains the purported opsonizing immunoglobulin. Alternatively,the opsonic ability is determined by measuring the numbers of viableorganisms before and after incubation. A reduced number of bacteriaafter incubation in the presence of immunoglobulin indicates a positiveopsonizing ability. In the cell-mediated bactericidal assay, positiveopsonization is determined by culturing the incubation mixture underappropriate bacterial growth conditions. Any significant reduction inthe number of viable bacteria comparing pre- and post-incubationsamples, or between samples which contain immunoglobulin and those thatdo not, is a positive reaction.

Clearance/protective Assays

Another preferred method of identifying agents for the treatment orprevention of a infection by Gram positive bacteria employs lethalmodels of sepsis that measure clearance and protection. Such agents canbe immunoglobulin or other antimicrobial substances.

A particularly useful animal model comprises administering an antibodyand a Gram positive organism to an immunocompromised (e.g., an immature)animal, followed by evaluating whether the antibody reduces mortality ofthe animal or enhances clearance of the organism from the animal. Thisassay may use any immature animal, including the rabbit, the guinea pig,the mouse, the rat, or any other suitable laboratory animal. Thesuckling rat lethal animal model is most preferred. Such a model canreadily incorporate an infected foreign body, such as an infectedcatheter, to more closely mimic the clinical setting. An alternativemodel utilizes adult susceptible animals, such as CF1 mice.

Clearance is evaluated by determining whether the pharmaceuticalcomposition enhances clearance of the infectious agent from the animal.This is typically determined from a sample of biological fluid, such asblood, peritoneal fluid, or cerebrospinal fluid. The infectious agent iscultured from the biological fluid in a manner suitable for growth oridentification of the surviving infectious agent. From samples of fluidtaken over a period of time after treatment, one skilled in the art candetermine the effect of the pharmaceutical composition on the ability ofthe animal to clear the infectious agent. Further data may be obtainedby measuring over a period of time, preferably a period of days,survival of animals to which the pharmaceutical composition isadministered. Typically, both sets of data are utilized. Results areconsidered positive if the pharmaceutical composition enhances clearanceor decreases mortality. In situations in which there is enhancedorganism clearance, but the test animals still perish, a positive resultis still indicated.

EXAMPLE 1 The Production of Hybridomas and Monoclonal Antibodies

To produce monoclonal antibodies that were directed against the surfaceproteins of S. epidermidis and were opsonic and protective for S.epidermidis, mice were immunized with whole S. epidermidis, Strain Hay.

A suspension of heat killed S. epidermidis was adjusted to an opticaldensity (OD) of 0.137 at a wavelength of 650 nm when measured through a1 centimeter light path. Bacteria from five mls of the suspension werepelleted by centrifugation (approximately 1800 X g, 10 minutes, roomtemperature). The supernatant was discarded and the pellet resuspendedin 0.6 mls of PBS, which was then mixed with 0.9 mls of completeFreund's adjuvant (CFA). The resulting emulsion was used as theimmunogen.

Adult, female BALB/c mice, obtained from Harlan Sprague Dawley(Indianapolis, Ind.) were immunized subcutaneously with 0.2 mls of theimmunogen described above. The mice received a booster immunizationapproximately two and ½ months later with antigen prepared as describedabove, except that incomplete Freund's adjuvant (IFA) was used as theadjuvant instead of CFA. A final, prefusion boost was givenapproximately two months after that. This boost consisted of 1 ml of S.epidermidis suspension (OD₆₅₀=0.137). Mice 8159 and 8160 each receivedan intraperitoneal injection of 0.5 mls of the suspension. Five dayslater, the spleen from mouse 8159 was removed and used for hybridomaformation.

Hybridomas were prepared by the general methods of Shulman, Wilde andKohler Nature 276:269-270 (1978) and Bartal and Hirshaut “CurrentMethods in Hybridoma Formation in Methods of Hybridoma Formation, Bartaland Heishaut, eds., Humana Press, Clifton, N.J. (1987). A total of2.135×10⁸ spleenocytes from mouse 8159 were mixed with 2.35×10⁷ SP2/0mouse myeloma cells (ATCC Catalog number CRL1581) and pelleted bycentrifugation (400 X g, 10 minutes at room temperature) and washed inserum free medium. The supernatant was removed to near-dryness andfusion of the cell mixture was accomplished in a sterile 50 mlcentrifuge conical by the addition of 1 ml of polyethylene glycol (PEG;mw 1400; Boehringer Mannheim) over a period of 60-90 seconds. The PEGwas diluted by slow addition of serum-free medium in successive volumesof 1, 2, 4, 8, 16 and 19 mls. The hybridoma cell suspension was gentlyresuspended into the medium and the cells pelleted by centrifugation(500 X g, 10 minutes at room temperature). The supernatant was removedand the cells resuspended in medium RPMI 1640, supplemented with 10%heat-inactivated fetal bovine serum, 0.05 mM hypoxanthine and 16 uMthymidine (HT medium). One hundred ul of the hybridoma cells wereplanted into 760 wells of 96-well tissue culture plates. Eight wells(column 1 of plate A) received approximately 2.5×10⁴ SP2/0 cells in 100ul. The SP2/0 cells served as a control for killing by the selectionmedium added 24 hours later.

Twenty four hours after preparation of the hybridomas, 100 ul of RPMI1640, supplemented with 10% heat-inactivated fetal bovine serums, 0.1 mMhypoxanthine, 0.8 uM aminopterin and 32 uM thymidine (HAT medium) wasadded to each well.

Ninety six hours after the preparation of the hybridomas, the SP2/0cells in plate A, column 1 appeared to be dead, indicating that the HATselection medium had successfully killed the unfused SP2/0 cells.

Eleven days after the preparation of the hybridomas, supernatants fromall wells were tested by ELISA for the presence of antibodies reactivewith methanol-fixed S. epidermidis. Based on the results of thispreliminary assay, cells from 20 wells were transferred to a 24-wellculture dish. Four days later, supernatant from these cultures wereretested by ELISA for the presence of antibodies reactive withmethanol-fixed S. epidermidis. Of these supernatants, one (from colony96-105CE11) was a strongly reactive IgG (Table 1). Two colonies(96-105FD4 and 96-105GB5) were very weakly reactive IgG's and one colony96-105HB10 was a weakly reactive IgM. Antibodies of the IgM isotype arenot as desirable as IgG's and culture 96-105HB10 was cryopreserved andnot further examined.

Cultures 96-105 CE11, FD4 and GB5 were reanalyzed several days later andonly CE11 showed a strong response (Table 2). No response was obtainedwith the other cell cultures, and no further experimental work was donewith them.

To further test the specificity of this antibody for S. epidermidis, awhole cell ELISA with several bacteria was performed (Table 3). Theantibodies from this colony bound strongly to S. epidermidis (Hay) O.D.1.090 and to a lesser degree to Group B streptococcus (GBS), but not toH. influenzae (HIB+, with type b capsule; HIB− without typable capsule)or type 14, pneumococcus (Pn 14).

A clone from 96-105CE11 IF6 was isolated and retested and was an IgG-1that reacted strongly with S. epidermidis (Strain Hay) in the whole cellELISA (Table 4). This clone was then designated 96-110. To determine if96-110 had the broad binding characteristics we sought and would beconsistent with binding to the surface protein on S. epidermidis (StrainHay) that bound broadly opsonic antibody, we ran a whole cell ELISAagainst several coagulase negative staphylococci (Table 5). Using 96-110in Ascites fluid, strong binding at several dilutions was detected forS. epidermidis type I, II, III, S. hemolyticus and S. hominus.

In addition, 96-110 MAB was purified over a protein G column(Pharmacia). Using a modification of the whole cell ELISA, peroxidaselabeled protein A was mixed with the purified 96-110 MAB and thenreacted with S. aureus type 5 (SA5) and S. aureus type 8 (SA8) obtainedfrom ATCC at Accession Nos. 12602 and 12605, respectively. Both S.aureus serotypes reacted strongly with the 96-110 MAB (Table 6). Since,in our previous studies, we found that absorption with S. epidermidis(Strain Hay) could decrease IgG opsonic activity and opsonic antibodiesraised against Hay reacted with a surface protein of Hay, we felt thatthis was still consistent with a MAB to the surface protein we weretrying to characterize. This finding was also important since types 5 &8, S. aureus are serotypes commonly associated with human infections.Using this protein A assay, MAB to type 14 pneumococcus did notdemonstrate binding to S. aureus.

Therefore, we have identified a mouse IgG₁ MAB raised against S.epidermidis (Strain Hay) that binds to the surface of both coagulasenegative and coagulase positive Staphylococci of Gram positive bacteria.Such an antibody would be valuable to prevent or treat infections ofGram positive cocci by preventing attachment of bacteria to epithelialcells or foreign bodies, by enhancing opsonization and protection frominfection and by reducing (down modulating) the inflammatory response.

TABLE 1 Immunoassay Results, 96-105 Supernatants on Methanol-Fixed S.Hay Colony Detection Specific For: ID G A M PBS-F 0.070 0.080 0.050 CE110.788 0.065 0.056 EB5 0.079 0.065 0.053 EE5 0.084 0.069 0.055 FD4 0.0890.067 0.059 FG4 0.087 0.065 0.065 FG8 0.090 0.060 0.062 FF9 0.095 0.0620.059 GE4 0.074 0.067 0.059 GB5 0.155 0.077 0.078 GB6 0.073 0.062 0.053GC6 0.069 0.062 0.052 GC9 0.076 0.062 0.053 GB10 0.075 0.064 0.102 HG20.195 0.067 0.059 HG3 0.079 0.066 0.060 HE4 0.076 0.073 0.065 HG4 0.0770.101 0.061 HG5 0.077 0.062 0.058 HC8 0.083 0.064 0.057 HB10 0.070 0.0640.223 AC4 IID10* 0.065 0.066 0.069 *Monoclonal antibody reactive withHib protein D.

TABLE 2 Immunoassay Results, 96-105 Supernatants on Methanol-Fixed S.Hay Colony Detection Specific For: ID G A M Buffer 0.052 0.045 0.045CE11 0.933 0.049 0.046 FD4 0.073 0.054 0.051 GB5 0.050 0.040 0.036

TABLE 3 Immunoassay Results 96-105 Supernatants on Methanol-FixedBacteria Colony Detection ID Antibody Hay Hib+ Hib− GBS Pn14 CE11gamma-specific 1.090 0.106 0.068 0.304 0.063 FE11 gamma-specific 0.1670.084 0.068 0.112 0.053 Buffer gamma-specific 0.048 0.075 0.056 0.0700.053 Several colonies from 96-105 not cloned.

TABLE 4 Assay of 96-105 CE11 IF6 on Various Bacteria Antibody AntigenDilution Isotype Hay Pn14 PBS-T 0.072 0.064 96-105CE11-IF6 Hay 2 IgG-1,k 1.608 0.099 4 1.184 0.087 8 0.846 0.069 16 0.466 0.074

TABLE 5 Detection of Bacteria of Anti-Hay Monoclonal* in Whole CellELISA Staph. Staph. Staph. Staph. Staph. Staph. Antibody Dilution HayEpi I Epi II Epi III Hemmolyt. Hominus Buffer 0.056 0.063 0.066 0.0550.058 0.074 96-110 100 1.448 2.334 1.524 1.241 1.197 0.868 Ascites 4001.325 2.542 0.746 0.425 0.830 0.422 1600 1.087 2.452 0.369 0.176 0.6800.185 6400 0.930 2.430 0.195 0.089 0.602 0.110 25600 6.674 1.672 0.1130.069 0.647 0.081 *Anti-Hay Monoclonal from unpurified ascites fluid

TABLE 6 Detection of Methanol-Fixed SA5, SA8 and S. Hay By PurifiedMonoclonal Anti-Hay Using Protein A Anti-Hay ATCC ATCC USU Dilution SA5SA8 Hay  500 1.329 3.345 3.017  1000 1.275 2.141 2.266  2000 0.873 1.0161.487  4000 0.333 0.491 0.951  8000 0.159 0.232 0.490 16000 0.132 0.1490.331 Normal Mouse 0.101 0.090 0.082  1000 Buffer 0.102 0.113 0.152Purified anti-Hay stock = 1.63 mg/ml

EXAMPLE 2

The Opsonic Activity of the Monoclonal Antibody

Antibodies which bind to an antigen may not necessarily enhanceopsonization or enhance protection from infection. Therefore, aneutrophil mediated bactericidal assay was used to determine thefunctional activity of antibody to S. epidermidis. Neutrophils wereisolated from adult venous blood by dextran sedimentation andficoll-hypaque density centrifugation. Washed neutrophils were added toround-bottomed wells of microtiter plates (approximately 10⁶ cells perwell) with approximately 3×10⁴ mid-log phase bacteria (S. epidermidisHay, ATCC 55133). Newborn lamb serum (10 uls), screened to assureabsence of antibody to S. epidermidis, was used as a source of activecomplement.

Forty microliters of immunoglobulin (or serum) were added at variousdilutions and the plates were incubated at 37° C. with constant,vigorous shaking. Samples of 10 uls were taken from each well at zerotime and after 2 hours of incubation. Each was diluted, vigorouslyvortexed to disperse the bacteria, and cultured on blood agar platesovernight at 37° C. to quantitate the number of viable bacteria. Resultsare presented as percent reduction in numbers of bacterial coloniesobserved compared to control samples.

Since the 96-110 MAB bound to both coagulase negative and coagulasepositive Staphylococci, opsonic studies were performed to determine ifthe MAB enhanced phagocytosis and killing of both groups ofstaphylococci. At a 1:80 dilution, the MAB enhanced opsonization andkilling of coagulase negative Staphylococcus (S. epidermidis) to 100%,compared with 49.5% with C′ and PMN alone (Table 7). The coagulasepositive Staphylococcus also showed enhanced phagocytosis at 1:10 and1:40 dilution (83.3% and 78.9% respectively) compared with 53.7 percentwith C′ and PMN alone. At 1:80 dilution, the opsonic activity against S.aureus was decreased to 61%.

These data show that not only does the MAB bind to the surface of bothcoagulase negative and coagulase positive Staphylococci, but that it hasfunctional activity and can enhance phagocytosis and killing of thesebacteria. Such an antibody would be capable of promoting clearance ofStaphylococci that have invaded a host and would be useful therapeuticagent.

TABLE 7 Opsonic Assay Antibody: Purified M X Hay, 96-110 Group Ab %Killed % Killed Description Dilution S. epidermidis S. aureus C′ only0.0 0.0 PMN only 0.0 0.0 PMN + C′ No Ab 49.5 53.7 PMN + Ab + C′ 10 —83.3 40 — 78.9 80 100.0 61.0

EXAMPLE 3 In vivo Protective Efficacy

Opsonic antibody correlates with enhanced protection from staphylococcalinfections, as set forth in the recent series of Fischer applicationsand issued patent described and incorporated by reference above. Tofurther demonstrate that the MAB can enhance survival to infections withboth coagulase positive and coagulase negative Staphylococci, studieswere conducted using lethal infection models.

Two day old Wistar rats were injected with −10⁶ S. aureus (type 5, ATCC12605) subcutaneously just cephalad to the tail. Approximately 30minutes before and 24 and 48 hours after infection, 0.2 ml MAB 96-110(⁻320 ug) was given IP. Control animals were given an equal volume ofsaline or a control MAB not directed against Staphylococci. All animalswere observed daily for five days to determine survival.

MAB 96-110 enhanced survival in this lethal neonatal model of coagulasepositive staphylococcus sepsis (FIG. 3):{fraction (8/15)} survived aftertreatment with MAB 96-110, and {fraction (0/10)} survived with ControlMAB or {fraction (2/25)} with saline treatment.

In a similar manner MAB 96-110 enhanced survival in adult mice infectedwith coagulase negative staphylococci. Adult CF1 mice were given 0.5 mlS. epidermidis (Hay) IP (3.5×10⁹ bacteria). About 24 hrs and 2 hrsbefore and 24 hrs post-infection, 320 ug of MAB 96-110 were given to onegroup of mice and compared with a second group infected in the samemanner, but not treated with antibody. All animals were followed 5 daysto determine survival. Approximately 23 hours after infection, 70% ofthe animals treated with MAB 96-110 were alive compared with 20% ofanimals not given antibody (FIG. 4). When the study was terminated 50%of the MAB animals remained alive compared to only 10% of controls.

Thus, MAB 96-110 could enhance survival in lethal coagulase positive andcoagulase negative staphylococcal infections. This enhancement occurredin an adult model and an immunocompromised model (immature neonatalimmune system).

EXAMPLE 4 Peptide Selection Panning Random 6 mer and 15 mer Fd-tet PhageLibraries

Amplified random 6 mer and 15 mer fd-tet phage libraries were pannedagainst the 96-110 antibody to yield populations of 6 and 15 amino acidlength peptides which cross react with the 96-110 antibody. The originallibraries were acquired from George P. Smith, Division of BiologicalSciences, University of Missouri, Columbia, Mo. In order to be used forpanning, the 96-110 antibody was crosslinked to Biotin using theSulfo-NHS-biotin ester crosslinking kit following the manufacturersprotocol (Pierce Chemical Co.).

For the first round of panning, 35 mm polystyrene petri dishes (Costar)were coated with streptavidin by incubating the plates overnight at 4°C. rocking with 100 mM NaHCO₃ and 10 ug streptavidin. Streptavidin wasthen discarded and plates were filled with blocking solution (0.1MNaHCO₃, 5 mg/ml dialyzed BSA, 0.1 ug/ml streptavidin) and incubated for1 hr at 4° C. The following protocol was then followed: Wash dishes sixtimes with TBS/Tween (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% v/v Tween20). Incubate dishes overnight at 4° C. rocking with 400 ul TBS/Tweencontaining 1 mg/ml dialyzed BSA and 10 ug biotinylated 96-110 antibody.Add 4 ul 10 mM biotin and allow to incubate 1 hr at 4° C. rocking. Washdishes six times as previously stated. Add 400 ul TBS/Tween into eachdish, add 4 ul 10 mM biotin and add approximately 5 ul of either the 6mer or 15 mer amplified fd-tet phage library (at 1×10¹⁴ vir/ml). Rockdishes 4 hrs at 4° C. Pour out phage and wash ten times with TBS/Tween.Incubate plates at room temp with 400 ul elution buffer (0.1N HCl, pHadjusted to 2.2 with glycine, 1 mg/ml BSA) for 10 min with rocking.Remove eluate to a Centricon 30 (Amicon) concentrator and bufferexchange with TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl) and concentrateto a volume of about 100 ul. Amplify eluate by mixing 100 ul eluate with100 ul K91 terrific broth cells and allowing phage to infect cells for10-30 min. Pipette infection mixture into 20 ml pre-warmed NZY medium(10 g NZ amine A, 5 g yeast extract, 5 g NaCl, 1 liter water, adjust topH 7.5, autoclave) containing 0.2 ug/ml tetracycline. Shake vigorouslyat 37° C. for 30-60 min. Add 20 ul of 20 mg/ml tetracycline stock to theflask. Remove a small sample for titering on plates and allow flask toshake vigorously overnight at 37° C. Calculate yield from biopanningusing the number of colonies counted on the titering plates fromamplification infection and the number of input phage at the beginningof panning. This number should amount to at least approximately 10⁻⁵%.Centrifuge 20 ml culture for 10 min at 5,000 rpm, then for 10 min at10,000 rpm; pour the doubly cleared supernatant into a fresh tubecontaining 3 ml PEG/NaCl (16.7% PEG 8000, 3.3M NaCl). Mix well and allowto incubate overnight at 4° C. Centrifuge tube 15 min at 10,000 rpm,discard supernatant and redissolve phage pellet in 1 ml TBS. Collectresuspended phage into a 1.5 ml eppendorf tube, clarify the suspensionby centrifugation, and add 150 ul PEG/NaCl. Allow to incubate on ice for1 hr. Microfuge the tube 10 min, discard supernatant, and redissolvephage in 200 ul TBS.

The second and third round of panning are carried out the same way. Theeluted, amplified phage (100 ul) from the previous panning ispreincubated with biotinylated 96-110 antibody (100 nM for the secondround; 0.1 nM for the third round) overnight at 4° C. 400 ul TBS/Tweenis added to the mixture and it is pipetted onto streptavidin coatedplates (prepared as previously stated) and then incubated with rockinggentle at room temperature for 10 min. The plates are then washed,eluted, and amplified as previously stated. The input and resultantphage are titered to determine yield from biopanning.

EXAMPLE5 Sequencing Resulting Phage Populations to Identify ConsensusSequences

After the third round of panning, the titered infection plates are usedto pick 20 single isolated colonies for each library. The colonies aregrown overnight in 5 ml NZY medium containing 40 ug/ml tetracycline.Replicative form DNA is extracted from each culture using Qiaplasmidquick prep kit (Qiagen Inc.) following the manufacturer's protocol.Media supernatants are saved for phage stock to be used in Example 4.2.5 ul of each RF DNA sample is added to a reaction containing 3.5 pmoleCLC502 primer (5′-TGAATTTTCTGTATGAGGTTT-3′) (SEQ ID NO 3), 8 Ul Prizmsequencing mix (ABI Inc.), QS to 20 ul with water and amplifiedfollowing manufacturers protocol. Successful sequences are translatedand aligned. 18 resulting sequences for the 6 mer library panning arelisted in FIG. 5. 18 resulting sequences for the second experiment 15mer library panning are listed in FIG. 6. 17 resulting sequences for thefirst experiment 15 mer library panning are listed in FIG. 7. A masterlist was compiled of the common resulting peptide sequences from all thepannings (FIG. 8) with the frequency of occurrence listed to the rightof each sequence. Consensus portions of the sequences are marked on themaster list (FIG. 8).

EXAMPLE 6 Phage EIA Comparing 3rd Round Phage Isolates Crossreactivityto 96-110 Antibody

The saved media phage stocks for each of the common resulting peptidesequences were amplified as previously stated. Amplified phagepreparations were quantitated by Abs₂₆₉ and diluted to 1×10¹³ vir/ml andserially diluted 1.2 seven times. A 96-well polystyrene plate was coatedwith 2 ug/ml streptavidin in 0.1M NaHCO₃ overnight at 4° C. Plates wereemptied and blocked for 1 hr at room temperature with phage blockingsolution, 100 ul/well. The following protocol was then followed. Washwells three times with TBS/Tween. Incubate overnight at 4° C. with 0.2ug/ml biotinylated 96110 in phage blocking solution, 100 ul/well. Washwells three times with TBS/Tween. Incubate overnight at 4° C. withserially diluted phage, 100 ul/well. Wash wells three times withTBS/Tween. Incubate 1 hr at room temperature with 1:5000 goat polyclonalanti-phage-HRP. Wash wells three times with TBS/Tween. Develop with 100ul ABTS substrate (Kirkegaard Perry) for 10-15 min and read absorbance(402 nm) on spectrophotometer according to manufacturer's protocol.Optical density signals of each phage isolate at 6.25×10¹¹ vir/ml arecompared in FIG. 9. The two isolates yielding the greatest signals are:

15mer2.12WRMYFSHRHAHLRSP(SEQ ID NO:1)

15mer2.1WHWRHRIPLQLAAGR(SEQ ID NO:2)

EXAMPLE 7 Antibodies Against Lipoteichoic Acid (LTA)

As set forth above, we identified two peptides that reacted with 96-110MAB. However, after identifying the peptides, the sequences did notcorrespond to any known proteins. Thus we began to consider otherpossible antigen candidates. We were surprised to find that MAB 96-110bound strongly to LTA from several gram positive bacteria such as S.mutans, S. aureus and S. faecalis (Table 8). In addition, in an ELISA,when the wells coated with S. epidermidis (Strain Hay) were reacted withMAB 96-110 inhibited by varying concentrations of LTA (from S. mutans,S. aureus and S. faecalis), reduction in MAB binding occurred (Table 9).The inhibition of MAB 96-110 binding was greatest at the highestconcentration of LTA inhibitor (9 ug/ml for each LTA) and variedaccording to which bacterial LTA was used (52% inhibition with S.mutans, 40.6% with S. aureus and 38.2% with S. faecalis).

The MAB 96-110 was also analyzed for binding to LTA from S. pyogenes(group A streptococcus) and various group A streptococcal M types. TheMAB showed strong binding to the LTA and also bound to the different Mtypes with strongest binding to M1 and M3 (Table 10).

We were surprised to find an antibody that bound to LTA and enhancedopsonization for both coagulase positive and coagulase negativestaphylococci in vitro and enhanced survival in lethal models ofstaphylococcal (coagulase negative and coagulase positive) sepsis, invivo. This is particularly surprising because the bacteria in each modelwere injected systemically (SQ or IP) and by-passed the epithelialbarriers (skin or mucous membranes) where LTA is thought to possibly actas an adherence factor for the bacteria to epithelial cells.

In addition, this strong anti-LTA reactivity will provide a method toblock the binding of LTA bearing bacteria to epithelial cells andprevent colonization of important pathogens such as staphylococci, groupA streptococci, S. faecalis (enterococci) and S. mutans. Since LTAinduces proinflammatory cytokines such as TNF, IL-6 and Interferongamma, MABs with strong anti-LTA binding will also have ananti-inflammatory action and modulate cytokine production secondary toLTA bearing bacteria. Anti-LTA antibodies or vaccines could be designedand produced to modulate cytokine production and inflammation in tissuesand prevent the adverse effects of these proinflammatory cytokines.

TABLE 8 Reactivity of Anti-Hay MAB 96-110 on wells Coated with SeveralLTA's Concentration LTA from LTA from S. LTA from S. Antibody ID orDilution S. mutans aureus faecalis Buffer 0.145 0.172 0.140 Anti-Hay 0.9 ug/ml 3.899 3.253 3.153 MAB  0.3 ug/ml 3.523 2.824 2.769 96-110 0.1 ug/ml 2.023 2.421 2.133 0.033 ug/ml 2.143 1.590 1.539 0.011 ug/ml1.396 0.998 0.832

TABLE 9 Inhibition of Anti-Hay MAB 96-110 with LTA From Different GramPositive Bacteria LTA Inhibitor LTA LTA LTA (ug/ml) S. mutans S. aureusS. faecalis 9 0.298 0.360 0.140 3 0.449 0.434 0.496 1 0.549 0.538 0.5450.37 0.558 0.526 0.549 0.12 0.509 0.735 0.582 0.04 0.574 0.614 0.671 00.621 0.607 0.648 NOTES: 1. Wells were coated with methanol-fixed Hay.2. Wells were blocked with 1% BSA in PBS. 3. Monoclonal anti-Hay wasused at a final concentration of 0.5 ug/ml and reacted with inhibitorsat the concentrations indicated in the Table. 4. Detection was with agamma-specific Rabbit anti-Mouse. 5. Substrate was TMB.

TABLE 10 Reactivity of MAB 96-110 on Whole Methanol Fixed Group A StrepGAS* GAS Type GAS Type GAS Type Dilution Type 1 3 18 24 Response onAntibody ID or Conc. #12344 #21546 #12357 #10782 pyogenes LTA Buffer0.511 0.161 0.234 0.148 0.075 Anti-Hay MAb 0.3 ug/ml 1.377 1.113 0.8440.566 — Anti-Hay Mab 0.1 ug/ml 1.016 0.553 0.555 0.402 2.228 *All GroupA Streptococcus (GAS) from ATCC (accession numbers noted above); plateswere coated with MeoH-fixed bacteria and read at 15 minutes.

EXAMPLE 8 Humanization of the Anti-Staph antibody 96-110 Cloning of the96-110 variable region cDNAs

The hybridoma cell producing the 96-110 antibody was obtained asdescribed above. A vial of cells was thawed, washed with serum freemedium and then resuspended in IMDM (Mediatech) complete mediasupplemented with 10% FBS (Irvine). Total RNA was isolated from 1×10⁸96-110 cells using the Midi RNA Isolation kit (Qiagen) following themanufacturer's procedure. The RNA was dissolved in 10 mM Tris, 0.1 mMEDTA (pH8.4) containing 0.03 U/μg Prime RNase Inhibitor (5′−3′) to afinal concentration of 0.25 μg/μl.

FIG. 10 shows the strategy for cloning the variable region genefragments and FIG. 11 lists the oligonucleotides primers used. The96-110 total RNA (2 μg) was converted to cDNA by using SuperscriptII-MMLV Reverse transcriptase (Life Technologies) and mouse kappa(OKA57) and mouse heavy chain (JS160-162)-specific priming according ofmanufacturer's procedures. The first strand cDNA synthesis products werethen purified using a Centricon-30 concentrator device (Amicon). Of the40 μl of cDNA recovered, 5 μl was used as template DNA for PCR.

Typical PCR amplification reactions (100 μl) contained template DNA, 50pmoles of the appropriate primers (PMC12-15,55 and OKA57 for tightchains, JSS1-4,8 and JS 160-162 for heavy chains), 2.5 units of ExTaqpolymerase (PanVera), 1x ExTaq reaction buffer, 200 μM dNTP, 1 mM MgCl₂.The template was denatured by an initial incubation at 96° C. for 5 min.The products were amplified by 15 thermal cycles of 55° C. for 30 sec.,70° C. for 30 sec, then 96° C. for 1 min. followed by 25 step cycles of70° C. for 1 min., then 96° C. for 1 min. The PCR products from thesuccessful reactions were purified using the Wizard PCR Purificationsystem (Promega) as per manufacturer's procedure.

The heavy chain PCR products (approximately 400 bp) were then clonedinto a bacterial vector for DNA sequence determination. Ligations of thePCR fragments were carried out into the PCR2.1 (invitrogen) T/A stylecloning vector following the manufacturer's procedures using a 3:1insert to vector molar ratio. One half (5 ul) of the ligation reactionswere used to transform Ultracompetent XL2BIue cells (Stratagene) as perthe manufacturer's procedure. Plasmid clones containing DNA inserts wereidentified using diagnostic restriction enzyme digestions with Ncol (NewEngland Biolabs). The DNA sequence of plasmids (pJRS308) containinginserts of the appropriate size (400 bp) was then determined. The finalconsensus DNA sequence of the heavy chain variable regions is shown inFIG. 12.

The light chain PCR products were treated differently. The hybridomacell line that expresses the 96-110 antibody was made by fusing mousespleenocytes with the SP20 myeloma cell line. The SP20 cell linetranscribes a pseudogene for the kappa light chain. In addition, thehybridoma cell line that expresses the 96-110 antibody transcribes asecond pseudogene product for a kappa light chain that apparently arosefrom the spleenocyte partner of the hybridoma fusion event. This secondpseudogene transcript can be expressed from an expression vectortransfected into mammalian cells, but this recombinant antibody productdoes not bind to heat-killed Staph HAY cells in an ELISA (see Example9). Both of these pseudogene transcripts, when converted to cDNA byRT-PCR, contain an Af/III restriction site. For this reason, the PCRproducts synthesized for the light chain variable region was digestedwith Af/III and those products that did not cut were then cloned intothe pGEM T-Easy (Promega) T/A style cloning vector using themanufacturer's procedures. Light chain candidate (pJRS319) clones weredigested with EcoRI (New England Biolabs) using the manufacturer'sprocedures to identify clones containing inserts of the appropriate size(350 bp). The final consensus DNA sequence of the light chain variableregions is shown in FIG. 12. The amino acids encoded by these sequencesmatch the N-terminal amino acid analyses of the heavy and light chainpeptide fragments produced by the hybridoma cell line.

The heavy and light chain variable regions were then subcloned into amammalian expression plasmid vector pSUN 15 for production ofrecombinant chimeric antibody molecules. The creation of the expressionvector was an extensive process of DNA fragment ligations and sitedirected mutagenesis steps. The result was a vector that expresses bothantibody chains with CMV promoter driven transcription. Neomycinresistance serves as a dominant selectable marker for transfection ofmammalian cells. In addition, it has been designed to allow convenientcloning of any light chain variable region as EcoRVIBstBI fragment, anyheavy chain variable region as a Nru|/EcoRI fragment, and any heavychain constant domain as an EcoRIINot/fragment. These restriction siteswere chosen because they occur rarely (if ever) in human and mousevariable regions. There is a mouse J region/kappa intron fragment fusedto a human kappa exon so that after post transcriptional splicing amouse human chimeric kappa light chain is produced.

The backbone of the vector was the plasmid pCDNA3 (Invitrogen). Thisplasmid was cut with HindIII/Xhol and a “light chain polylinker” DNAfragment was inserted to create the stated “light chain vector.” Thislinker contained the restriction sites HindIII, KpnI, Cla, Pm/I, EcoRVXmal, BamHI and Xhol to facilitate subsequent cloning steps to createthe plasmid pCDNA3.LCPL. A Smal/BcII DNA fragment containing a lightchain leader, anti-CKMB kappa light chain genomic fragment, and 3′ UTRwas cloned into the EcoRV/BamHI sites of pCDNA3.LCPL. The mouse kappaintron, exon and 3′ UTR in this fragment was derived from LCPXK2received from Dr. Richard Near (Near, RI et al, 1990, Mol Immunol.27:901-909). Mutagenesis was then performed to eliminate an Nrul (209),MIul (229). and BstBl (2962) and to introduce an Nhel (1229) and a BamHI(1214) site to create pCDNA3mut.LCPL.LCVK.

A second “heavy chain vector” was constructed from the pCDNA3mut.LCPL.LCVK plasmid by replacing the light chain expression region(HindIII/Xhol) with a “heavy chain polylinker” consisting of restrictionsites Hpal, BspEl, EcoRV, Kpnl, and Xhol. A Smal/Kpnl DNA fragmentcontains a heavy chain leader, antiCKMB IgG2b chain genomic fragment. AKpnl/Sall oligo nucleotide fragment containing a 3′ UTR and a Notlupstream of the Sall site was subsequently cloned into the KpnI1Xholdigested plasmid, (knocking out the Xhol site) to create the plasmidpCDNA3mut.HCPL.HCV2b. From this point two vectors were created that didnot have any of the anti-CKMB variable or constant domain DNA sequences.This was done by cutting the plasmid pCDNA3mut.LCPL.LCVK with EcoRV/Xholand inserting a linker oligonucleotide fragment containing EcoRV, BstBl,and Xhol sites to create pSUN9. In a similar way, the anti-CKMB fragmentin pCDNA3mut.HCPL.HCV2b (Nrul/Notl) was replaced by a linkeroligonucleotide fragment containing Nrul, EcoRI and Notl sites to createpSUN10. A human kappa light chain constant domain was then cloned intopSUN9 as a BstB/Xhol fragment, and a human IgG1 constant domain wascloned into pSUN10 as a EcoRI/Notl fragment. A BgIII/Nhel fragment fromthe human heavy chain vector was then cloned into the human light chainvector cut with BamHI/Nhel to create pSUNI5. This vector results in theproduction of recombinant antibody molecules under the control of theCMV transcriptional promoters. The heavy chain molecules are direct cDNAconstructs that fuse the variable region sequence directly into thehuman IgG1 constant domain. The light chain molecules, on the otherhand, have a mouse kappa intron region 3′ of the variable region codingfragment. After splicing the variable region becomes fused to a humankappa constant region exon. The selectable marker for the vector inmammalian coils is Neomycin (G418).

The variable region gene fragments were re-amplified by PCR usingprimers that adapted the fragments for cloning into the expressionvector (see FIGS. 12 and 14). The heavy chain front primer (96110HF2)includes a 5′ tail that encodes the C-terminus of the heavy chain leaderand an Nrul restriction site for cloning, while the heavy chain reverseprimer (96110HB) adds a 3′ EcoRI restriction site for cloning. The lightchain front primer (96110bLF) converts the first amino acid of the96-110 light chain variable region sequence from glutamine (Q) toaspartic acid (D) via the introduction of an EcoRV restriction site atthe N-terminus of the light chain variable region for cloning, while thelight chain reverse primer (96-110bLB) adds a 3′ DNA sequence for thejoining region-kappa exon splice junction followed by a BstB1restriction site for cloning. Because the last amino acid of the lightchain variable region is an arginine (R) which is a very rare amino acidat this position, the reverse primer introduces a point mutation in thecodon for amino acid 106 that converts it to the much more common lysine(L). This was done because the splice junction in the expression vectorfor the kappa chain was derived from a J region that encoded a lysine atthis position. Neither mutation in the recombinant form of the antibodywould be anticipated to alter the antibodies binding characteristics.

PCRs were performed as described above except 10 ng of plasmid templatewas used in each case. Following a 5 min. incubation at 96° C., the PCRperimeters were 35 thermal cycles of 58° C. for 30 sec., 70° C. for 30sec., and 96° C. for 1 min.

The 96-110 heavy chain PCR product (approximately 400 bp) was digestedwith Nrul and EcoRI (New England Biolabs), purified using a Qiaquick PCRPurification column (Qiagen), as described by the manufacturer, andligated into NruI/EcoRI digested and gel-purified pSUN15, resulting inplasmid pJRS311 (see FIG. 13).

At this point a BstBl/NotI (New England Biolabs) DNA fragment containinga mouse kappa J-kappa intron fragment fused to a human kappa exonfragment was digested and gel-purified from the vector tKMC180C1. Thisfragment was ligated into the backbone of pJRS311 digested withBstBl/Notl and gel-purified resulting in the plasmid pJRS315 (see FIG.13).

This was the plasmid into which was cloned the 96-110 light chainvariable region. The 96-110 light chain PCR product (approximately 350bp) was digested with EcoRV and BstBl (New England Biolabs), purifiedusing a Qiaquick PCR Purification column (Qiagen), as described by themanufacturer, and ligated into EcoRV/Bs/Bl digested and gel-purifiedpJRS315, resulting in plasmid pJRS326 (see FIG. 13).

It was determined that during this cloning process, a deletion ofapproximately 200 bp occurred at the intron exon junction of the kappalight chain. To repair this, an identical DNA fragment (also a BstB/NotIrestriction fragment) was gel-purified from digested pEN22 and ligatedinto BstBl/Notl digested and gel-purified pJRS326, resulting in thefinal expression plasmid construct pJRS334 (see FIGS. 13 and 14). Thesequence of the variable regions and leader and other junctions wasverified prior to mammalian cell transfection.

EXAMPLE 9 Transient Production of Recombinant Chimeric Mouse/human96-110 Antibody

Two individual clones of the plasmid pJRS334 (pJRS334-1, -2) weretransfected into COS and CHO cells using Superfectant (Qiagen) in 6 welltissue culture cells as described by the manufacturer. After three daysthe supernatant was assayed for the production of “humanized” antibodyand for the capability for the expressed antibody to bind to theheat-killed Staph antigen.

Antibody production assays were preformed in 8-well strips from 96-wellmicrotiter plates (Maxisorp F8; Nunc, Inc.) coated at a 1:500 dilutionwith Goat anti-Human IgG antibody (Pierce) using a bicarbonate coatingbuffer, pH 8.5. The plates are covered with pressure sensitive film(Falcon, Becton Dickinson) and incubated overnight at 4° C. Plates arethen washed once with Wash solution (Imadazole/NaCl/0.4% Tween-20). 100microliters of culture supernatant was then applied to duplicate wellsand allowed to incubate for 30 minutes on plate rotator at roomtemperatures. The plates were washed five times with Wash solution. AGoat anti Human kappa-HRP (Southern Biotechnologies) conjugate wasdiluted 1:800 in the sample/conjugate diluent. 100 microliters was addedto the samples, then incubated on a plate rotator for 30 minutes at roomtemperature. The samples were washed as above and then incubated with100 μL/well of ABTS developing substrate (Kirkgaard & PerryLaboratories) for 10-15 minutes on a plate rotator at room temperature.The reaction was stopped with 100 μL/well of Quench buffer (Kirkgaard &Perry Laboratories) and the absorbance value at 405 nm was determinedusing an automated microtiter plate ELISA reader (Ceres UV900HI,Bioteck, Winooski, Vt.). As a positive control, a humanized mouse/humanchimeric antibody BC24 was used. This assay (see FIG. 15) demonstratesthat the transfection of cells with this plasmid construct to results inthe cells producing a molecule containing both human IgG and kappadomains. The supernatants were then assayed for the ability of theexpressed antibodies to bind to heat-killed Staph. The activity assayswere preformed in 8-well strips from 96-well microtiter plates (MaxisorpF8; Nunc, Inc.) coated at 0.09 OD/well with heat-killed Staph Hay cellmaterial suspended in MeOH. The plates are left uncovered and incubatedovernight at 4° C. Plates are then washed once PBS. 100 microliters ofculture supernatant was then applied to duplicate wells and allowed toincubate for 60 minutes on plate rotator at room temperature. The plateswere washed five times with Wash solution. The goat anti Human kappa-HRPwas diluted 1:800 in the sample/conjugate diluent. 100 microliters wasadded to the samples, then incubated on a plate rotator for 30 minutesat room temperatures. The samples were washed as above and thenincubated with 100 μL/well of ABTS developing substrate (Kirkgaard &Perry Laboratories) for 10-15 minutes on a plate rotator at roomtemperature. The reaction was stopped with 100 μL/well of Quench buffer(Kirkgaard & Perry Laboratories) and the absorbance value at 405 nm wasdetermined using an automated microtiter plate ELISA reader (CeresUV900HI, Bioteck, Winooski, Vt.). As a positive control, the originalmouse monoclonal antibody 96-110 was used, and assayed with a Goatanti-Mouse Fc-HRP conjugate @ 1:2000 dilution. This assay (see FIG. 16)demonstrates that the transfection of cells with this plasmid constructto results in the cells producing a molecule that binds to the Staph Haycellular antigen.

EXAMPLE 10 Stable Production of Recombinant Chimeric Mouse/human 96-110Antibody

The plasmid pJRS334-1 was transfected into NS/0 cells (obtainable fromBaxter International) and CHO cells using electroporation. The plasmidwas linearized with Pvul restriction digestion. 25 micrograms ofdigested plasmid DNA was mixed with 1×10⁷ cells in a total volume of 800microliters in a 4 centimeter cuvette and subjected to a pulse of 250mA, 9600 microF. The cells were plated out after 24 hours in 10 mlnon-selective media. The cells were then diluted out into 96-wellmicrotiter plates. As colonies appeared, the supernatants were assayedfor the production of “humanized” antibody and for the capability forthe expressed antibody to bind to the heat-killed Staph antigen.Antibody production and activity assays for the stable transfectantswere performed as described above. These assays demonstrate that thetransfection of cells with this plasmid construct can result in theproduction of a stable cell line that produces a humanized chimericversion of the 96-110 mouse hybridoma antibody.

EXAMPLE 11 Opsonic Activity

Having produced a chimeric anti-LTA MAB for staphylococci, we tested itsfunctional activity using S. epidermidis as a representativestaphylococcal organism. Using the neutrophil mediated opsonophagocyticassay described generally in the Material and Methods section, weassessed the MAB's opsonic activity by evaluating the percent ofbacteria killed after two hours of incubation.

Neutrophils, specifically polymorphonuclear neutrophils, were isolatedfrom adult venous blood by dextran sedimentation and ficoll-hypaquedensity centrifugation. Washed neutrophils were added to round-bottomedwells of microtiter plates (approximately 10⁶ cells per well) withapproximately 3×10⁴ mid-log phase bacteria (S. epidermidis Hay, ATCC55133). Human sera (10 uls), screened to assure absence of antibody toS. epidermidis, was used as a source of active complement (C-Barb-Ex(1:4)).

Forty microliters of immunoglobulin were added at various concentrations(20 ug/ml, 40 ug/ml, 80 ug/ml, and 160 ug/ml) and the plates wereincubated at 37° C. with constant, vigorous shaking. Samples of 10 ulswere taken from each well at zero time and after 2 hours of incubation.Each was diluted, vigorously vortexed to disperse the bacteria, andcultured on blood agar plates overnight at 37° C. to quantitate thenumber of viable bacteria. Results are presented in FIG. 17 as percentreduction in numbers of bacterial colonies observed compared to controlsamples. Compared to PMN alone or PMN plus complement, the addition ofthe MAB markedly enhanced opsonic activity for staphylococcus at 20-160ug/ml). These data demonstrate that the MAB has functional activity andcan enhance the phagocytosis and killing of staphylococcal organisms, asrepresented by S. epidermidis.

EXAMPLE 12 In Vivo Protective Efficacy

Using the lethal staphylococcal sepsis in adult mice assay (described inExample 3), we compared protection between the original mouse MAB andthe chimeric HuMAB. Adult CF1 mice were given 0.5 ml S. epidermidis(Hay) IP (3.5×10⁹ bacteria). About 24 hrs and 1 hr before infection, 14mg/kg of each MAB was given to a group of mice, with a third group ofmice given only PBS. All animals were followed for 40 hours afterchallenge to determine survival.

As set forth in FIG. 18, approximately 18 hours after infection, all thecontrol animals died while both treatment groups exhibited 100%survival. At 30 hours after infection, both MAB treatment groupsexhibited 70% survival. At the end of the study, the group that receivedthe mouse MAB exhibited greater survival than the group receiving thechimeric MAB, but both MAB enhanced survival over the PBS controls.

We conducted further studies with the chimeric MAB at a dose of 18mg/kg/dose 2 doses given IP 24 and 1 hour prior to infection (3×10⁹ IPS. epidermidis, Hay). As set forth in FIG. 19, the chimeric MAB enhancedsurvival. We also assessed the effect of the chimeric MAB on bacteremiain the lethal S. epidermidis sepsis model. CF-1 mice were twice infectedIP with strain Hay and the chimeric MAB. Bacteremia is expressed as thenumber of bacteria isolated on blood agar after a 1:1000 dilutions. Asset forth in FIG. 20, the chimeric MAB reduced bacterial levels by over2 logs. Additional studies demonstrated that bacteremia was reduced to agreater degree using 40 mg/kg/dose compared to 20 mg/kg/dose even ifsurvival was comparable. See FIG. 21.

These data indicate that increasing the amount of antibody resulted inincreased bacterial clearance in vivo. Such a response is similar to theobserved enhanced opsonic activity in vitro as seen when antibody wasincreased from 20 ug/mg to 160 ug/ml in the neutrophil mediatedopsonophagocytic assay (FIG. 17).

EXAMPLE 13 In Vivo Protective Efficacy

The effect of the chimeric MAB 96-110 was then analyzed in a neonatalstaphylococcal model using suckling rats with a foreign body infection.Two day old Wistar rats were treated with lipid emulsion (as is standardin newborn care for nutritional purposes) 0.2 ml, 20% IP on day−1 andagain on day+1 and +2 to induce further compromise of the immuno system.In two studies, we injected approximately 5×10⁷ of four differentstrains of S. epidermidis, identified below in Table 11 SQ through aplastic catheter and the catheter was left in place under the skin.Saline, 0.2 ml, or MAB 96-110, 0.2 ml (dose of 50-60 mg/kg), was givenIP 30 min before and 24 hours after infection. The animals were followedfor 5 days.

As set forth in Table 11, in study 1, survival for animals receiving MABranged from 67% to 83%, with an average of 76%, in contrast to salinetreatment, which ranged from 33% to 50%, with an average of 39%. StudyII showed even more impressive results. Survival for animals treatedwith MAB ranged from 83% to 100%, with 90% average, compared to thesaline controls at 33% to 50%, with an average of 40%. The complied datafor study II are shown in FIG. 22.

TABLE 11 The Effect of Hu96-110 on Survival in a Lethal Neonatal S.epidermidis Sepsis Model Monoclonal Antibody Saline Control Litter S.epidermidis Survived Survived Number strain Treated (%) Treated (%)Study 1 31 Haywood(type II) 6 4(67%) 6 2(33%) (clinical) 32 35984(typeI) 5 4(80%) 4 2(50%) (Prototype) 33 Summer(48357) 6 4(67%) 6 2(33%)(clinical) 34 SE-360(type III) 6 5(83%) 6 2(33%) (Prototype) 35Haywood(type II) 6 5(83%) 6 3(50%) (clinical) TOTAL 29 22(76%)  2811(39%)  Study II 36 Haywood(type II) 6  6(100%) 6 3(50%) (clinical) 3735984(type I) 6 5(83%) 6 2(33%) (Prototype) 38 Summer(48357) 6  6(100%)6 2(33%) (clinical) 39 SE-360(type III) 6 5(83%) 6 2(33%) (Prototype) 40Haywood(type II) 6 5(83%) 6 3(50%) (clinical) TOTAL 30 27(90%)  3012(40%)  TOTAL OF BOTH STUDIES 59 49(88%)  58 23(40%) 

These data demonstrate that the chimeric human antibody directed againstLTA is opsonic and enhances survival against staphylococci. In addition,the antibody promotes clearance of the staphylococci form the blood.Thus antibody to LTA provides prophylactic and therapeutic capabilitiesagainst staphylococcal infections and vaccines using LTA or peptidemimeotopes of LTA that induce anti-LTA antibodies would also haveprophylactic capabilities.

Having now fully described the invention, it will be appreciated bythose skilled in the art that the invention can be performed within arange of equivalents and conditions without departing from the spiritand scope of the invention and without undue experimentation. Inaddition, while the invention has been described in light of certainembodiments and examples, the inventors believe that it is capable offurther modifications. This application is intended to cover anyvariations, uses, or adaptions of the invention which follow the generalprinciples set forth above.

The specification includes recitation to the literature and thoseliterature references are herein specifically incorporated by reference.

The specification and examples are exemplary only with the particularsof the claimed invention set forth as follows:

89 15 amino acids amino acid <Unknown> linear peptide 1 Trp Arg Met TyrPhe Ser His Arg His Ala His Leu Arg Ser Pro 1 5 10 15 15 amino acidsamino acid <Unknown> linear peptide 2 Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly Arg 1 5 10 15 21 base pairs nucleic acid singlelinear other nucleic acid /desc = “primer” 3 TGAATTTTCT GTATGAGGTT T 2130 base pairs nucleic acid single linear cDNA CDS 1..30 4 GGG GCT CATGCG GAT AGG GTT TAT GGG GCC 30 Gly Ala His Ala Asp Arg Val Tyr Gly Ala 15 10 10 amino acids amino acid linear protein 5 Gly Ala His Ala Asp ArgVal Tyr Gly Ala 1 5 10 30 base pairs nucleic acid single linear cDNA CDS1..30 6 GGG ANT CAT GCG GAT AGG GTT TAT GGG GCC 30 Gly Xaa His Ala AspArg Val Tyr Gly Ala 1 5 10 10 amino acids amino acid linear protein 7Gly Xaa His Ala Asp Arg Val Tyr Gly Ala 1 5 10 57 base pairs nucleicacid single linear cDNA CDS 1..57 8 GGG GCT TGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 9 Gly Ala Trp His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 10 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 11 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 12 GGG GCT TGG AAG GCT TTG TTT AGT CATTCT TAT CGT CCT CGG GGT TCG 48 Gly Ala Trp Lys Ala Leu Phe Ser His SerTyr Arg Pro Arg Gly Ser 1 5 10 15 GCT GGG GCC 57 Ala Gly Ala 19 aminoacids amino acid linear protein 13 Gly Ala Trp Lys Ala Leu Phe Ser HisSer Tyr Arg Pro Arg Gly Ser 1 5 10 15 Ala Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 14 GGG GCT AGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Arg His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 15 Gly Ala Arg His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 16 GGG GCT TGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 17 Gly Ala Trp His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 18 GGG GCT TGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 19 Gly Ala Trp His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 20 GGG GCT CAG GTG GCT GTT TTG TAT CCTCCT TTG GCT GAT GCT ACT GAG 48 Gly Ala Gln Val Ala Val Leu Tyr Pro ProLeu Ala Asp Ala Thr Glu 1 5 10 15 CTT GGG GCC 57 Leu Gly Ala 19 aminoacids amino acid linear protein 21 Gly Ala Gln Val Ala Val Leu Tyr ProPro Leu Ala Asp Ala Thr Glu 1 5 10 15 Leu Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 22 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 23 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 24 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 25 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 26 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 27 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 28 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 29 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 30 GGG GCT TGG CGG AAG TAT TTT TCT TATCAT CAT GCG CAT CTT TGT AGT 48 Gly Ala Trp Arg Lys Tyr Phe Ser Tyr HisHis Ala His Leu Cys Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 31 Gly Ala Trp Arg Lys Tyr Phe Ser TyrHis His Ala His Leu Cys Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 32 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 33 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 34 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 35 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 36 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 37 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 38 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 39 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 40 GGG GCT TGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 41 Gly Ala Trp His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 42 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 43 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 44 GGG GCT GAT TGG ATT ACT TTT CAT CGTCGT CAT CAT GAT CGT GTT CTT 48 Gly Ala Asp Trp Ile Thr Phe His Arg ArgHis His Asp Arg Val Leu 1 5 10 15 TCT GGG GCC 57 Ser Gly Ala 19 aminoacids amino acid linear protein 45 Gly Ala Asp Trp Ile Thr Phe His ArgArg His His Asp Arg Val Leu 1 5 10 15 Ser Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 46 GGG GCT GGT TGG ATT ACT TTT CAT CGTCGT CAT CAT GAT CGT GTT CTT 48 Gly Ala Gly Trp Ile Thr Phe His Arg ArgHis His Asp Arg Val Leu 1 5 10 15 TCT GGG GCC 57 Ser Gly Ala 19 aminoacids amino acid linear protein 47 Gly Ala Gly Trp Ile Thr Phe His ArgArg His His Asp Arg Val Leu 1 5 10 15 Ser Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 48 GGG GCT GGG AAG GCT ATG TTT AGT CATTCT TAT CGT CAT CGG GGT TCG 48 Gly Ala Gly Lys Ala Met Phe Ser His SerTyr Arg His Arg Gly Ser 1 5 10 15 GCT GGG GCC 57 Ala Gly Ala 19 aminoacids amino acid linear protein 49 Gly Ala Gly Lys Ala Met Phe Ser HisSer Tyr Arg His Arg Gly Ser 1 5 10 15 Ala Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 50 GGG GCT GAT TGG ATT ACT TTT CAT CGTCGT CAT CAT GAT CGT GTT CTT 48 Gly Ala Asp Trp Ile Thr Phe His Arg ArgHis His Asp Arg Val Leu 1 5 10 15 TCT GGG GCC 57 Ser Gly Ala 19 aminoacids amino acid linear protein 51 Gly Ala Asp Trp Ile Thr Phe His ArgArg His His Asp Arg Val Leu 1 5 10 15 Ser Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 52 GGG GCT AGT CGT CAT ATG CTT GCT CGGTGG TCG CGT TTG CTT GCT GTT 48 Gly Ala Ser Arg His Met Leu Ala Arg TrpSer Arg Leu Leu Ala Val 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 53 Gly Ala Ser Arg His Met Leu Ala ArgTrp Ser Arg Leu Leu Ala Val 1 5 10 15 Pro Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 54 GGG GCT GGG AAG GCT ATG TTT AGT CATTCT TAT CGT CAT CGG GGT TCG 48 Gly Ala Gly Lys Ala Met Phe Ser His SerTyr Arg His Arg Gly Ser 1 5 10 15 GCT GGG GCC 57 Ala Gly Ala 19 aminoacids amino acid linear protein 55 Gly Ala Gly Lys Ala Met Phe Ser HisSer Tyr Arg His Arg Gly Ser 1 5 10 15 Ala Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 56 GGG GCT TGG CAT TGG CGT CAT CGT ATTCCT CTT CAG CTT GCT GCT GGT 48 Gly Ala Trp His Trp Arg His Arg Ile ProLeu Gln Leu Ala Ala Gly 1 5 10 15 CGT GGG GCC 57 Arg Gly Ala 19 aminoacids amino acid linear protein 57 Gly Ala Trp His Trp Arg His Arg IlePro Leu Gln Leu Ala Ala Gly 1 5 10 15 Arg Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 58 GGG GCT CGT CGG CAT GGT AAT TTT TCTCAT TTT TTT CAT CGG TCG TTG 48 Gly Ala Arg Arg His Gly Asn Phe Ser HisPhe Phe His Arg Ser Leu 1 5 10 15 ATT GGG GCC 57 Ile Gly Ala 19 aminoacids amino acid linear protein 59 Gly Ala Arg Arg His Gly Asn Phe SerHis Phe Phe His Arg Ser Leu 1 5 10 15 Ile Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 60 GGG GCT TGG AAG GCT TTG TTT AGT CATTCT TAT CGT CCT CGG GGT TCG 48 Gly Ala Trp Lys Ala Leu Phe Ser His SerTyr Arg Pro Arg Gly Ser 1 5 10 15 GCT GGG GCC 57 Ala Gly Ala 19 aminoacids amino acid linear protein 61 Gly Ala Trp Lys Ala Leu Phe Ser HisSer Tyr Arg Pro Arg Gly Ser 1 5 10 15 Ala Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 62 GGG GCT CAG GTG GCT GTT TTG TAT CCTCCT TTG GCT GAT GCT ACT GAG 48 Gly Ala Gln Val Ala Val Leu Tyr Pro ProLeu Ala Asp Ala Thr Glu 1 5 10 15 CTT GGG GCC 57 Leu Gly Ala 19 aminoacids amino acid linear protein 63 Gly Ala Gln Val Ala Val Leu Tyr ProPro Leu Ala Asp Ala Thr Glu 1 5 10 15 Leu Gly Ala 57 base pairs nucleicacid single linear cDNA CDS 1..57 64 GGG GCT TGG CGT ATG TAT TTT TCT CATCGT CAT GCG CAT CTT CGT AGT 48 Gly Ala Trp Arg Met Tyr Phe Ser His ArgHis Ala His Leu Arg Ser 1 5 10 15 CCT GGG GCC 57 Pro Gly Ala 19 aminoacids amino acid linear protein 65 Gly Ala Trp Arg Met Tyr Phe Ser HisArg His Ala His Leu Arg Ser 1 5 10 15 Pro Gly Ala 30 base pairs nucleicacid single linear cDNA CDS 1..30 66 GGG GCT CAT GCG GAT AGG GTT TAT GGGGCC 30 Gly Ala His Ala Asp Arg Val Tyr Gly Ala 1 5 10 10 amino acidsamino acid linear protein 67 Gly Ala His Ala Asp Arg Val Tyr Gly Ala 1 510 45 base pairs nucleic acid single linear other nucleic acid /desc =“primer” 68 ATTTCAGGCC CAGCCGGCCA TGGCCGARGT RMAGCTKSAK GAGWC 45 45 basepairs nucleic acid single linear other nucleic acid /desc = “primer” 69ATTTCAGGCC CAGCCGGCCA TGGCCGARGT YCARCTKCAR CARYC 45 45 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 70ATTTCAGGCC CAGCCGGCCA TGGCCCAGGT GAAGCTKSTS GARTC 45 45 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 71ATTTCAGGCC CAGCCGGCCA TGGCCGAVGT GMWGCTKGTG GAGWC 45 45 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 72ATTTCAGGCC CAGCCGGCCA TGGCCCAGGT BCARCTKMAR SARTC 45 35 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 73GCTGCCACCG CCACCTGMRG AGACDGTGAS TGARG 35 35 base pairs nucleic acidsingle linear other nucleic acid /desc = “primer” 74 GCTGCCACCGCCACCTGMRG AGACDGTGAS MGTRG 35 35 base pairs nucleic acid single linearother nucleic acid /desc = “primer” 75 GCTGCCACCG CCACCTGMRG AGACDGTGASCAGRG 35 32 base pairs nucleic acid single linear other nucleic acid/desc = “primer” 76 CCCGGGCCAC CATGGAGACA GACACACTCC TG 32 35 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 77CCCGGGCCAC CATGGATTTT CAAGTGCAGA TTTTC 35 32 base pairs nucleic acidsingle linear other nucleic acid /desc = “primer” 78 CCCGGGCCACCATGGAGWCA CAKWCTCAGG TC 32 33 base pairs nucleic acid single linearother nucleic acid /desc = “primer” 79 CCCGGGCCAC CATGKCCCCW RCTCAGYTTCTKG 33 31 base pairs nucleic acid single linear other nucleic acid /desc= “primer” 80 CCCGGGCACC ATGAAGTTGC CTGTTAGGCT G 31 23 base pairsnucleic acid single linear other nucleic acid /desc = “primer” 81GCACCTCCAG ATGTTAACTG CTC 23 54 base pairs nucleic acid single linearother nucleic acid /desc = “primer” 82 TAATATCGCG ACAGCTACAG GTGTCCACTCCCGAAGTGAT GCTGGTGGAG WCTG 54 30 base pairs nucleic acid single linearother nucleic acid /desc = “primer” 83 TTATAGAATT CTGAGGAGAC GGTGAGTGAG30 29 base pairs nucleic acid single linear other nucleic acid /desc =“primer” 84 TTAGGCGATA TCGTTCTCTC CCAGTCTCC 29 46 base pairs nucleicacid single linear other nucleic acid /desc = “primer” 85 GTAACCGTTCGAAAAGTGTA CTTACGTTTT ATTTCCAGCA TGGTCC 46 369 base pairs nucleic acidsingle linear cDNA CDS 1..369 86 GAA GTG ATG CTG GTG GAG TCT GGT GGA GGATTG GTG CAG CCT AAA GGG 48 Glu Val Met Leu Val Glu Ser Gly Gly Gly LeuVal Gln Pro Lys Gly 1 5 10 15 TCA TTG AAA CTC TCA TGT GCA GCC TCT GGATTC ACC TTC AAT AAC TAC 96 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly PheThr Phe Asn Asn Tyr 20 25 30 GCC ATG AAT TGG GTC CGC CAG GCT CCA GGA AAGGGT TTG GAA TGG GTT 144 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys GlyLeu Glu Trp Val 35 40 45 GCT CGC ATA AGA AGT AAA AGT AAT AAT TAT GCA ACATTT TAT GCC GAT 192 Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr PheTyr Ala Asp 50 55 60 TCA GTG AAA GAC AGG TTC ACC ATC TCC AGA GAT GAT TCACAA AGC ATG 240 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser GlnSer Met 65 70 75 80 CTC TAT CTG CAA ATG AAC AAC TTG AAA ACT GAG GAC ACAGCC ATG TAT 288 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr AlaMet Tyr 85 90 95 TAC TGT GTG AGA CGG GGG GCT TCA GGG ATT GAC TAT GCT ATGGAC TAC 336 Tyr Cys Val Arg Arg Gly Ala Ser Gly Ile Asp Tyr Ala Met AspTyr 100 105 110 TGG GGT CAA GGA ACC TCA CTC ACC GTC TCC TCA 369 Trp GlyGln Gly Thr Ser Leu Thr Val Ser Ser 115 120 123 amino acids amino acidlinear protein 87 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val GlnPro Lys Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe ThrPhe Asn Asn Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys GlyLeu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala ThrPhe Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp AspSer Gln Ser Met 65 70 75 80 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr GluAsp Thr Ala Met Tyr 85 90 95 Tyr Cys Val Arg Arg Gly Ala Ser Gly Ile AspTyr Ala Met Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Ser Leu Thr Val SerSer 115 120 318 base pairs nucleic acid single linear cDNA CDS 1..318 88CAA ATT GTT CTC TCC CAG TCT CCA GCA ATC CTG TCT GCA TCT CCA GGG 48 GlnIle Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15GAA AAG GTC ACA ATG ACT TGC AGG GCC AGC TCA AGT GTA AAT TAC ATG 96 GluLys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met 20 25 30 CACTGG TAC CAG CAG AAG CCA GGA TCC TCC CCC AAA CCC TGG ATT TCT 144 His TrpTyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Ser 35 40 45 GCC ACATCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT 192 Ala Thr SerAsn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 GGG TCT GGGACC TCT TAC TCT CTC ACA ATC AGC AGA GTG GAG GCT GAA 240 Gly Ser Gly ThrSer Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 GAT GCT GCCACT TAT TAC TGC CAG CAG TGG AGT AGT AAC CCA CCC ACG 288 Asp Ala Ala ThrTyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr 85 90 95 TTC GGA GGG GGGACC ATG CTG GAA ATA AGA 318 Phe Gly Gly Gly Thr Met Leu Glu Ile Arg 100105 106 amino acids amino acid linear protein 89 Gln Ile Val Leu Ser GlnSer Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr MetThr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met 20 25 30 His Trp Tyr Gln GlnLys Pro Gly Ser Ser Pro Lys Pro Trp Ile Ser 35 40 45 Ala Thr Ser Asn LeuAla Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr SerTyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 Asp Ala Ala ThrTyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr 85 90 95 Phe Gly Gly GlyThr Met Leu Glu Ile Arg 100 105

We claim:
 1. A chimeric immunoglobulin chain comprising at least part ofa human immunogobulin constant region and at least part of a nonhumanimmunoglobulin variable region having specificity to lipoteichoic acidof Gram positive bacteria.
 2. The chimeric immunoglobulin chain of claim1, wherein the constant region is selected from IgG, IgA, and IgM. 3.The chimeric immunoglobulin chain of claim 1, wherein the chain isselected from a heavy chain and a light chain.
 4. The chimericimmunoglobulin chain of claim 1, wherein the chain is a light chainselected from a kappa chain and a lambda chain.
 5. The chimericimmunoglobulin chain of claim 1, wherein the chain enhances theopsonization of Gram positive bacteria by 75% or more over background.6. The chimeric immunoglobulin chain of claim 1, wherein the chain (a)binds to lipoteichoic acid at a level that is twice the background orgreater and (b) enhances the opsonization of Gram positive bacteria by75% or more over background.
 7. The chimeric immunoglobulin chain ofclaim 1, wherein the chain is part of an antibody fragment chosen fromat least one of Fab, Fab′, F(ab′)₂, and SFv.
 8. The chimericimmunoglobulin chain of claim 1, wherein the chain further recognizes apeptide sequence chosen from: WRMYFSHRHAHLRSP(SEQ ID NO:1); andWHWRHRIPLQLAAGR(SEQ ID NO:2).
 9. The chimeric immunoglobulin chain ofclaim 1, wherein the variable region's Complementarity DeterminingRegions correspond to at least one of the Complementarity DeterminingRegions of FIG.
 12. 10. A composition comprising the chimericimmunoglobulin chain of claim 1 and a pharmaceutically acceptablecarrier.
 11. The composition of claim 10, wherein the composition iscomprised of regions or derivatives of the chimeric immunoglobulinchain, wherein the regions or derivatives of the chimeric immunoglobulinchain have specificity to lipoteichoic acid of Gram positive bacteria,and a pharmaceutically acceptable carrier.
 12. The composition of claim11, wherein the region is a Complementarity Determining Region.
 13. Thecomposition of claim 11, wherein the derivative is comprised of proteinsor peptides encoded by truncated or modified antibody genes.
 14. Thecomposition of claim 11, wherein the chimeric immunoglobulin chain ispart of an antibody fragment chosen from at least one of Fab, Fab′,F(ab′)₂, and SFv.
 15. A chimeric immunoglobulin chain comprising atleast part of a human immunoglobulin constant region and at least partof a nonhuman immunoglobulin variable region having specificity tolipoteichoic acid of Gram positive bacteria, wherein the variableregion's Complementarity Determining Region amino acid sequences are atleast 70% homologous to the Complementarity Determining Region aminoacid sequences of FIG. 12 chosen from at least one of: amino acids 31-35of SEQ ID NO. 87, amino acids 50-68 of SEQ ID NO. 87 amino acids 101-112of SEQ ID NO. 87, amino acids 24-33 of SEQ ID NO. 89, amino acids 49-55of SEQ ID NO. 89, and amino acids 88-96 of SEQ ID NO.
 89. 16. A peptidecharacterized by amino acids corresponding to at least one of theComplementarity Determining Regions of a variable region of FIG. 12,wherein the variable region is chosen from at least one of SEQ ID NO 87and SEQ ID NO
 89. 17. The peptide of claim 16, wherein the variableregion is selected from a heavy chain or a light chain.
 18. A peptidecharacterized by amino acids corresponding to at least one of theComplementarity Determining Regions of a variable region of FIG. 12,wherein the Complementarity Determining Region amino acid sequences ofthe peptide are at least 70% homologous to the ComplementarityDetermining Region amino acid sequences chosen from at least one of:amino acids 31-35 of SEQ ID NO. 87, amino acids 50-68 of SEQ ID NO. 87,amino acids 101-112 of SEQ ID NO. 87, amino acids 24-33 of SEQ ID NO.amino acids 49-55 of SEQ ID NO. 89, and amino acids 88-96 of SEQ IDNO.89.
 19. A composition comprising at least one peptide of claims 16,17, or 18 and a pharmaceutically acceptable carrier.